

## INVITATION TO BID



# health

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

## HP09-2026SD

# SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2026 TO 30 APRIL 2029

**BID VALIDITY PERIOD: 180 DAYS**

**NON-COMPULSORY ONLINE BRIEFING SESSION:  
MS TEAMS WEBINAR: 20 JUNE 2025 AT 10:00**



# health

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. DR AB Xuma Building, 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA 0187  
Directorate: Affordable Medicines

Ref: HP09-2026SD

e-mail: [tenders@health.gov.za](mailto:tenders@health.gov.za)

## INVITATION TO BID: HP09-2026SD

### SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2026 TO 30 APRIL 2029

1. Kindly furnish the Department of Health with a tender for the supplies shown on the attached forms.
2. Included are the General Conditions of Contract (GCC), Special Requirements and Conditions of Contract (SRCC) as well as the Standard Bidding Document (SBD) and Pharmaceutical Bidding Document (PBD) forms listed on the annexure hereto. The Bid Response Document is available as a separate Excel file.
3. The Invitation to Bid document, with all pages and forms completed in detail, must be returned with your bid (marked Set 1). Include a USB flash drive with a scanned copy of the completed bid (marked Set 2). Scanned files in Set 2, must be in the exact compilation sequence as per index. All Excel spreadsheets as Set 3, must be on USB flash drive for uploading purposes.
4. All sets to be in a single sealed package with the following information on the outside of the package: Bid number and Closing date of bid, Full name and address of the bidder, Return address and Name of Contact person.
5. The bid must be addressed to the Director-General, Department of Health, and be deposited into the pharmaceutical tender box as indicated on the SBD1 form not later than the closing date and time of the bid. The tender box is located at the main entrance of the Department of Health, DR AB Xuma Building, located at 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA.

*K. Jamaloodien*

**Ms K Jamaloodien**

**CHIEF-DIRECTOR: SECTOR-WIDE PROCUREMENT**

**For: Director-General**

**Date: 06/06/2025**

## **CONTACT PERSONS AT THE NATIONAL DEPARTMENT OF HEALTH**

Please direct any queries relating to the bidding process to [tenders@health.gov.za](mailto:tenders@health.gov.za)

### **BID DOCUMENTS FOR COMPLETION AND SUBMISSION**

All bid documents must be compiled, indexed, and submitted in the exact sequence specified. Each document must include the relevant annexure, as indicated in the bid document checklist (Annexure A) attached to the bid pack.

- Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.
- All bid documents must be signed in the spaces provided within the document, preferably in permanent black ink.
- All bid documents must be initialled at the bottom of each page in the space provided with "Bidder's Signature...", preferably in permanent black ink.
- Where certified copies of original documents are submitted, bidders must ensure that the certification is original, signed, and dated by the Commissioner of Oaths.
- If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths.
- All SBD bid documents must fully signed and witnessed, where required, preferably in permanent black ink. All mandatory documents as specified in Annexure A must be valid at the time of bid closure. The NDoH will not accept updated mandatory bid documents after the bid closure date, unless the document was valid at the time of bid closure but is set to expire during the bid validity period. In such cases, an updated document may only be submitted if specifically requested by the Department.

Bidders who do not comply with any of the mandatory requirements will be deemed non-responsive and may not be considered for evaluation.

- Covering Letter
- Bid/File Index
- PBD 3: Bid Signature. Resolution/Authority to sign bid.
- SBD 1: Invitation to bid
- PBD 4.1: Contact Details of Bidder.
- Consortium, Joint Venture (incorporated or unincorporated) and Partnership – Certified copy of relevant agreement between entities, and any other documents as specified.

- CSD Registration report - A certified copy of latest report.
- Tax Clearance Pin Issued by SARS.
- CIPC/CIPRO or proof of ownership/shareholding certificates. Certified copies of registration certificates Proof of company ceding mergers, acquisition and name changes including shareholding certificates to claim for preference points for RDP goal: Promotion of South African owned enterprises.
- Name Change - Proof of company ceding mergers, acquisition, and name changes
- PBD9.1: Directors: Categorization of Directors profile (Excel spreadsheet) Certified copies of Directors identification
- ID - Certified copies of Directors/Owners Identification listed in PBD9.1
- SBD 4: Declaration of interest
- PBD 8: Special Requirements and Conditions of Contract. Declaration of compliance.
- SBD 6(1) Indicate Preference Points Claimed in table and spaces provided.
- Certified copies of South African Identification, (RSA ID) – franchise in national elections before the 1983 and 1993.
- Certified copies of South African Identification, (RSA ID) – Who is female
- Certified copies of South African Identification, (RSA ID) – Who has a disability
- Certified copies of South African Identification, (RSA ID) for owners of the South African owned enterprise complying with the mandatory administrative and technical requirements of this bid as set out in paragraphs 3 and 4
- Certified copies of the share certificate(s) reflecting the number of shares held by Member(s) and/or Director(s) of the enterprise who claims points for the promotion of South African owned enterprises.
- Note or documentation from a registered Medical doctor as evidence of disability
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.
- GMP – LM - SAHPRA approved GMP certificate as alternative to PBD5 (Local manufacturers)
- SBD5: The National Industrial Participation Programme.
- License to manufacture or import (in the name of the bidder), including all annexures. Certified copies required.
- License to manufacture/import distribute/wholesale Complementary Medicines ,including all annexures and DA02 product list.
- License to manufacture or import, including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant). Certified copies required.
- Medicine Registration Certificates (MRC) with all the associated conditions of registration, and Variation Summary - Certified copies required.

- A valid Variation Summary for any changes on the MRC where applicable as prescribed by SAHPRA GUIDELINE: BAU VARIATIONS COMMUNICATION, latest version
- PBD1: Authorization Declaration: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.
- PBD 1.1: List of products offered sourced from third party.
- PBD 1.2: Unconditional written undertaking from the third party.
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered
- Proof of sample submission
- Bidder's item list (list of products offered). Signed Excel Bid Response i.e.: Pricing Schedule.
- Set 2 & 3 - Universal Serial Bus (USB) Flash Drive / Storage Device with digital copy of the completed bid.

## COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time in a sealed package. A scanned PDF of the Hard Copy of Set 1, (signed legal documents, including all certificates and documents requested) must be named Set 2 and saved together with Set 3 on a Universal Serial Bus (USB) Flash Drive / Storage Device. Set 3 comprising of all fully electronically completed excel spreadsheets. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

### **Set 1: Hard copy legally binding bid documents**

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten. All bid documents must be signed in ink in the spaces provided within the document. All bid documents must be initialed at the bottom of each page in ink in the space provided i.e. "Bidder's signature...".

Where certified copies of original documents are submitted, bidders must ensure that the certification is original and dated by the Commissioner of Oaths. Where applicable, all bid documents must be witnessed in ink

The signed hard copy of the bid document will serve as the legal bid document.

Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorized designee of the entity submitting the bid must sign the official signature pages.

All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

**Note Set 2 & 3 - Bidders must submit a Universal Serial Bus (USB) Flash Drive / Storage Device with a digital copy of the completed bid. Bidders are required to follow the exact compilation sequence as per the index and use the index admin code abbreviation used in the file name.**

**Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)**

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

**Set 3: Electronic version of bid documents**

Bidders must submit the electronic versions, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated. Ensure that the bid price is offered for the product as specified.

Bidders must ensure that the price quoted for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied

## INVITATION TO BID

SBD 1

**YOU ARE HEREBY INVITED TO BID FOR REQUIREMENTS OF THE NATIONAL  
DEPARTMENT OF HEALTH**

BID NUMBER: HP09-2026SD

CLOSING DATE: 4 AUGUST 2025

CLOSING TIME: 11:00

**DESCRIPTION     Supply and Delivery of Solid Dosage Forms to the Department of Health  
for the period 01 May 2026 to 30 April 2029**

Bid documents must be addressed as follows and delivered before the closing date and time:

**Addressed to:**


The Director-General: Health  
Dr AB Xuma Building  
1112 Voortrekker Road  
**PRETORIA**

**Delivered to:**

Directorate: Affordable Medicines  
Dr AB Xuma Building  
1112 Voortrekker Road, Block A  
Pretoria Townlands 351-JR  
**PRETORIA**  
0187

**Bidders should ensure that bids are delivered on time to the correct address and deposited in the Tender Box. Late bids will not be accepted for consideration**

The Pharmaceutical Tender Box is generally accessible during working hours.  
See below for map locating Dr AB Xuma Building within Pretoria.



**ALL BIDS MUST BE SUBMITTED ON THE OFFICIAL FORMS**

This competitive bidding process is subject to the Preferential Procurement Policy Framework Act and the Preferential Procurement Regulations, 2022, the General Conditions of Contract (GCC) and, if applicable, any other Special Requirements and Conditions of Contract.



## PART A INVITATION TO BID

<b>YOU ARE HEREBY INVITED TO BID FOR REQUIREMENTS OF THE (NAME OF DEPARTMENT/ PUBLIC ENTITY)</b>					
BID NUMBER:	HP09-2026SD	CLOSING DATE:	4 AUGUST 2025	CLOSING TIME:	11:00
DESCRIPTION	SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2026 TO 30 APRIL 2029				
BID RESPONSE DOCUMENTS MAY BE DEPOSITED IN THE BID BOX SITUATED AT 1112 VOORTREKKER ROAD, PRETORIA TOWNLANDS 351-JR, PRETORIA					
<b>PHARMACEUTICAL TENDER BOX</b>					
<b>RECEPTION AREA</b>					
<b>NATIONAL DEPARTMENT OF HEALTH</b>					
<b>DR AB XUMA BUILDING</b>					
<b>BIDDING PROCEDURE ENQUIRIES MAY BE DIRECTED TO</b>			<b>TECHNICAL ENQUIRIES MAY BE DIRECTED TO:</b>		
CONTACT PERSON			CONTACT PERSON		
TELEPHONE NUMBER			TELEPHONE NUMBER		
FACSIMILE NUMBER			FACSIMILE NUMBER		
E-MAIL ADDRESS	tenders@health.gov.za		E-MAIL ADDRESS	tenders@health.gov.za	
<b>SUPPLIER INFORMATION</b>					
NAME OF BIDDER					
POSTAL ADDRESS					
STREET ADDRESS					
TELEPHONE NUMBER	CODE		NUMBER		
CELLPHONE NUMBER					
FACSIMILE NUMBER	CODE		NUMBER		
E-MAIL ADDRESS					
VAT REGISTRATION NUMBER					
SUPPLIER COMPLIANCE STATUS	TAX COMPLIANCE SYSTEM PIN:		OR	CENTRAL SUPPLIER DATABASE No:	MAAA
ARE YOU THE ACCREDITED REPRESENTATIVE IN SOUTH AFRICA FOR THE GOODS /SERVICES OFFERED?	<input type="checkbox"/> Yes <input type="checkbox"/> No [IF YES ENCLOSE PROOF]		ARE YOU A FOREIGN BASED SUPPLIER FOR THE GOODS /SERVICES OFFERED?		<input type="checkbox"/> Yes <input type="checkbox"/> No [IF YES, ANSWER THE QUESTIONNAIRE BELOW]
<b>QUESTIONNAIRE TO BIDDING FOREIGN SUPPLIERS</b>					
IS THE ENTITY A RESIDENT OF THE REPUBLIC OF SOUTH AFRICA (RSA)?				<input type="checkbox"/> YES <input type="checkbox"/> NO	
DOES THE ENTITY HAVE A BRANCH IN THE RSA?				<input type="checkbox"/> YES <input type="checkbox"/> NO	
DOES THE ENTITY HAVE A PERMANENT ESTABLISHMENT IN THE RSA?				<input type="checkbox"/> YES <input type="checkbox"/> NO	
DOES THE ENTITY HAVE ANY SOURCE OF INCOME IN THE RSA?				<input type="checkbox"/> YES <input type="checkbox"/> NO	
IS THE ENTITY LIABLE IN THE RSA FOR ANY FORM OF TAXATION?				<input type="checkbox"/> YES <input type="checkbox"/> NO	
<b>IF THE ANSWER IS "NO" TO ALL OF THE ABOVE, THEN IT IS NOT A REQUIREMENT TO REGISTER FOR A TAX COMPLIANCE STATUS SYSTEM PIN CODE FROM THE SOUTH AFRICAN REVENUE SERVICE (SARS) AND IF NOT REGISTER AS PER 2.3 BELOW.</b>					

## PART B

### TERMS AND CONDITIONS FOR BIDDING

<b>1. BID SUBMISSION:</b>
1.1. BIDS MUST BE DELIVERED BY THE STIPULATED TIME TO THE CORRECT ADDRESS. LATE BIDS WILL NOT BE ACCEPTED FOR CONSIDERATION.
1.2. <b>ALL BIDS MUST BE SUBMITTED ON THE OFFICIAL FORMS PROVIDED (NOT TO BE RE-TYPED) OR IN THE MANNER PRESCRIBED IN THE BID DOCUMENT.</b>
1.3. THIS BID IS SUBJECT TO THE PREFERENTIAL PROCUREMENT POLICY FRAMEWORK ACT, 2000 AND THE PREFERENTIAL PROCUREMENT REGULATIONS, THE GENERAL CONDITIONS OF CONTRACT (GCC) AND, IF APPLICABLE, ANY OTHER SPECIAL CONDITIONS OF CONTRACT.
1.4. <b>THE SUCCESSFUL BIDDER WILL BE REQUIRED TO FILL IN AND SIGN A WRITTEN CONTRACT FORM (SBD7).</b>
<b>2. TAX COMPLIANCE REQUIREMENTS</b>
2.1 BIDDERS MUST ENSURE COMPLIANCE WITH THEIR TAX OBLIGATIONS.
2.2 BIDDERS ARE REQUIRED TO SUBMIT THEIR UNIQUE PERSONAL IDENTIFICATION NUMBER (PIN) ISSUED BY SARS TO ENABLE THE ORGAN OF STATE TO VERIFY THE TAXPAYER'S PROFILE AND TAX STATUS.
2.3 APPLICATION FOR TAX COMPLIANCE STATUS (TCS) PIN MAY BE MADE VIA E-FILING THROUGH THE SARS WEBSITE WWW.SARS.GOV.ZA.
2.4 BIDDERS MAY ALSO SUBMIT A PRINTED TCS CERTIFICATE TOGETHER WITH THE BID.
2.5 IN BIDS WHERE CONSORTIA / JOINT VENTURES / SUB-CONTRACTORS ARE INVOLVED; EACH PARTY MUST SUBMIT A SEPARATE TCS CERTIFICATE / PIN / CSD NUMBER.
2.6 WHERE NO TCS PIN IS AVAILABLE BUT THE BIDDER IS REGISTERED ON THE CENTRAL SUPPLIER DATABASE (CSD), A CSD NUMBER MUST BE PROVIDED.
2.7 NO BIDS WILL BE CONSIDERED FROM PERSONS IN THE SERVICE OF THE STATE, COMPANIES WITH DIRECTORS WHO ARE PERSONS IN THE SERVICE OF THE STATE, OR CLOSE CORPORATIONS WITH MEMBERS PERSONS IN THE SERVICE OF THE STATE."

**NB: FAILURE TO PROVIDE / OR COMPLY WITH ANY OF THE ABOVE PARTICULARS MAY RENDER THE BID INVALID.**

SIGNATURE OF BIDDER: .....

CAPACITY UNDER WHICH THIS BID IS SIGNED: .....  
(Proof of authority must be submitted e.g. company resolution)

DATE: .....

**BID SIGNATURE AUTHORISATION (PBD3)**

To confirm the authorised signatory for this bid

**1. BIDDING ENTERPRISE TYPE**

Please indicate by ticking the appropriate box:

Company	Close Corporation	Incorporated JV	Partnership / Consortium / Unincorporated JV

**2. AUTHORISATION**

Bidding Enterprise Name:.....

Enterprise Registration Number (CIPC):.....

I/We, the undersigned, being the Directors / Members / Owners / Partners of the bidding enterprise listed in Table 1, hereby authorise the individual/s listed in Table 2, to sign all documents in connection with this bid and any contract resulting therefrom on behalf of the bidding enterprise.

TABLE 1 - Directors / Members / Owners / Partners of the bidding enterprise				
Name (Print)	Representing (enterprise)	ID number	Signature	Date

(Add rows if needed)

TABLE 2 - Authorised Signatory/Signatories				
Name (Print) Authorised Signatory	Position in Bidding Enterprise	ID number	Signature	Date

**3. MANDATORY RESOLUTION REQUIREMENT**

**For Companies, Close Corporations and Incorporated Joint Ventures:** Attach a certified board/member resolution.

**For Joint Ventures, Consortiums and Partnerships:** Attach a signed resolution/agreement by all partners, indicating the authorised signatory and joint/several liability.

**The PBD3 must be accompanied by a certified resolution from the board / members/ partners, confirming the authority to sign. The absence of the supporting resolution will render the bid non-responsive, regardless of the PBD3 being signed.**



# health

Department:  
Health  
REPUBLIC OF SOUTH AFRICA

PBD4.1

Private Bag X828, PRETORIA, 0001. DR AB Xuma Building, 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA 0187. Directorate: Access to Affordable Medicines Tel: (012) 395 8130 Fax: (012) 395 8823/4

**CONTRACT NUMBER:** \_\_\_\_\_

**SUPPLIER DETAILS:**

Note that Provincial Departments of Health will require separate registration of Suppliers on their Databases & could request completion of Province-specific documents.

If a contract is awarded, full detail for supplier registration or verification will be requested.

Should any of the detail provided below change, please advise the National Department of Health immediately in writing with detail of such change(s).

**CONTACT DETAIL**

<b>1. Supplier Registered Name</b> <i>Legal entity / corresponding with banking detail</i>			
<b>2. Contact person regarding contract enquiries (to be printed on contract cover)</b>			
Name & Surname			e-mail
Telephone		Fax	
Cell		Other	
<b>3. Contact regarding orders</b>			
Address for posting of orders		Fax	
		Tel (confirmation)	
		EDI	
<b>Order enquiries</b>	Name & surname:	Tel	
		e-mail	
<b>4. National key Account Manager (or Tender Manager)</b>			
Name			e-mail
Telephone		Cell	

TENDER NO				LEGAL NAME OF BIDDING ENTERPRISE				PBD9-1	
DIRECTORS CATEGORISATION									
Directors - Full Names		Surname	Nationality	Identity Number or Passport Number (foreigner)	Are you appointed as a Director? Y/N	Executive or Non-Executive director	Ownership or Director in related enterprise/s whether or not such enterprise/s are bidding in this tender? (Y/N)		If Yes, specify
OWNERSHIP CATEGORISATION									
CLOSE CORPORATION (YES - NO)	COMPANY (YES - NO)	INCORPORATED JOINT VENTURE (YES - NO)	PARTNERSHIP (YES - NO)	JOINT VENTURE UNINCORPORATED (YES - NO)	CONSORTIUM (YES -NO)	LISTED COMPANY (YES - NO)		Select appropriate category	
OWNERSHIP IN THE BIDDING ENTERPRISE HELD BY INDIVIDUALS									
Owners - (Individuals) Full Names	Surname	Nationality	RSA Identity Number or Foreign Passport Number	Race Categorisation	Is this owner HDI as per SRCC HDI definition YES/NO	Gender	Disability (Yes/No)	% Shareholding in bidding enterprise	
OWNERSHIP IN THE BIDDING ENTERPRISE HELD BY LEGAL ENTITIES									
Ownership - Legal Entities Name	Company Reg No	% Shareholding							

## BIDDER'S DISCLOSURE

### 1. PURPOSE OF THE FORM

Any person (natural or juristic) may make an offer or offers in terms of this invitation to bid. In line with the principles of transparency, accountability, impartiality, and ethics as enshrined in the Constitution of the Republic of South Africa and further expressed in various pieces of legislation, it is required for the bidder to make this declaration in respect of the details required hereunder.

Where a person/s are listed in the Register for Tender Defaulters and / or the List of Restricted Suppliers, that person will automatically be disqualified from the bid process.

### 2. Bidder's declaration

- 2.1 Is the bidder, or any of its directors / trustees / shareholders / members / partners or any person having a controlling interest<sup>1</sup> in the enterprise, employed by the state? **YES/NO**

- 2.1.1 If so, furnish particulars of the names, individual identity numbers, and, if applicable, state employee numbers of sole proprietor/ directors / trustees / shareholders / members/ partners or any person having a controlling interest in the enterprise, in table below.

Full Name	Identity Number	Name of State institution

- 2.2 Do you, or any person connected with the bidder, have a relationship

---

<sup>1</sup> the power, by one person or a group of persons holding the majority of the equity of an enterprise, alternatively, the person/s having the deciding vote or power to influence or to direct the course and decisions of the enterprise.

**SBD4**

with any person who is employed by the procuring institution? **YES/NO**

2.2.1 If so, furnish particulars:

.....  
 .....

2.3 Does the bidder or any of its directors / trustees / shareholders / members / partners or any person having a controlling interest in the enterprise have any interest in any other related enterprise whether or not they are bidding for this contract? **YES/NO**

2.3.1 If so, furnish particulars:

.....  
 .....

### **3 DECLARATION**

I, \_\_\_\_\_ the \_\_\_\_\_ undersigned,  
 (name)..... in  
 submitting the accompanying bid, do hereby make the following  
 statements that I certify to be true and complete in every respect:

- 3.1 I have read and I understand the contents of this disclosure;
- 3.2 I understand that the accompanying bid will be disqualified if this disclosure is found not to be true and complete in every respect;
- 3.3 The bidder has arrived at the accompanying bid independently from, and without consultation, communication, agreement or arrangement with any competitor. However, communication between partners in a joint venture or consortium<sup>2</sup> will not be construed as collusive bidding.
- 3.4 In addition, there have been no consultations, communications, agreements or arrangements with any competitor regarding the quality, quantity, specifications, prices, including methods, factors or formulas used to calculate prices, market allocation, the intention or decision to submit or not to submit the bid, bidding with the intention not to win the bid and conditions or delivery particulars of the products or services to which this bid invitation relates.
- 3.4 The terms of the accompanying bid have not been, and will not be, disclosed by the bidder, directly or indirectly, to any competitor, prior to the date and time of the official bid opening or of the awarding of the contract.
- 3.5 There have been no consultations, communications, agreements or arrangements made by the bidder with any official of the procuring

---

<sup>2</sup> Joint venture or Consortium means an association of persons for the purpose of combining their expertise, property, capital, efforts, skill and knowledge in an activity for the execution of a contract.

**SBD4**

institution in relation to this procurement process prior to and during the bidding process except to provide clarification on the bid submitted where so required by the institution; and the bidder was not involved in the drafting of the specifications or terms of reference for this bid.

- 3.6 I am aware that, in addition and without prejudice to any other remedy provided to combat any restrictive practices related to bids and contracts, bids that are suspicious will be reported to the Competition Commission for investigation and possible imposition of administrative penalties in terms of section 59 of the Competition Act No 89 of 1998 and or may be reported to the National Prosecuting Authority (NPA) for criminal investigation and or may be restricted from conducting business with the public sector for a period not exceeding ten (10) years in terms of the Prevention and Combating of Corrupt Activities Act No 12 of 2004 or any other applicable legislation.

I CERTIFY THAT THE INFORMATION FURNISHED IN PARAGRAPHS 1, 2 and 3 ABOVE IS CORRECT.

I ACCEPT THAT THE STATE MAY REJECT THE BID OR ACT AGAINST ME IN TERMS OF PARAGRAPH 6 OF PFMA SCM INSTRUCTION 03 OF 2021/22 ON PREVENTING AND COMBATING ABUSE IN THE SUPPLY CHAIN MANAGEMENT SYSTEM SHOULD THIS DECLARATION PROVE TO BE FALSE.

.....	.....
Signature	Date
.....	.....
Position	Name of bidder



## DECLARATION OF COMPLIANCE WITH THE SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

*To be signed by the Chief Executive Officer (CEO) of the Company in terms of this bid.*

I, .....  
(Full name)

with the following identity number .....

being the Chief Executive Officer (CEO) of .....

.....  
(Organisation/Company Legal Name)

hereby declares that

.....  
(Organisation/Company Legal Name)

will comply with all the requirements and conditions as stipulated in the Special  
Requirements and Conditions of Contract (SRCC).

..... Signature CEO	..... (Signed at Location)	..... (on date)
------------------------	-------------------------------	--------------------

..... Witness Signature	..... (Signed at Location)	..... (on date)
----------------------------	-------------------------------	--------------------

## PREFERENCE POINTS CLAIM FORM IN TERMS OF THE PREFERENTIAL PROCUREMENT REGULATIONS 2022

This preference form must form part of all tenders invited. It contains general information and serves as a claim form for preference points for specific goals.

**NB: BEFORE COMPLETING THIS FORM, TENDERERS MUST STUDY THE GENERAL CONDITIONS, DEFINITIONS AND DIRECTIVES APPLICABLE IN RESPECT OF THE TENDER AND PREFERENTIAL PROCUREMENT REGULATIONS, 2022**

### 1. GENERAL CONDITIONS

1.1 The following preference point systems are applicable to invitations to tender:

- the 90/10 system for requirements with a Rand value above R50 000 000 (all applicable taxes included).

1.2 The applicable preference point system for this tender is the 90/10 preference point system.

1.3 Points for this tender (even in the case of a tender for income-generating contracts) shall be awarded for:

- (a) Price; and
- (b) Specific Goals.

1.4 The maximum points for this tender are allocated as follows:

	POINTS
<b>PRICE</b>	<b>90</b>
<b>SPECIFIC GOALS</b>	<b>10</b>
<b>Total points for Price and SPECIFIC GOALS</b>	<b>100</b>

1.5 Failure on the part of a tenderer to submit proof or documentation required in terms of this tender to claim points for specific goals with the tender, will be interpreted to mean that preference points for specific goals are not claimed.

1.6 The organ of state reserves the right to require of a tenderer, either before a tender is adjudicated or at any time subsequently, to substantiate any claim in regard to preferences, in any manner required by the organ of state.

1.7 The company must submit ID Copies of Director/Owner/Shareholder/Trustee and Beneficiary with their bid document to substantiate points claimed. The share certificate(s) reflecting the number of shares held by each Director/Owner/Shareholder/Trustee and Beneficiary must be submitted. In the case

of claiming points for disability the company must submit a registered Doctor's note or document as evidence of the disability

## 2. DEFINITIONS

- (a) **“tender”** means a written offer in the form determined by an organ of state in response to an invitation to provide goods or services through price quotations, competitive tendering process or any other method envisaged in legislation;
- (b) **“price”** means an amount of money tendered for goods or services, and includes all applicable taxes less all unconditional discounts;
- (c) **“rand value”** means the total estimated value of a contract in Rand, calculated at the time of bid invitation, and includes all applicable taxes;
- (d) **“tender for income-generating contracts”** means a written offer in the form determined by an organ of state in response to an invitation for the origination of income-generating contracts through any method envisaged in legislation that will result in a legal agreement between the organ of state and a third party that produces revenue for the organ of state, and includes, but is not limited to, leasing and disposal of assets and concession contracts, excluding direct sales and disposal of assets through public auctions; and
- (e) **“the Act”** means the Preferential Procurement Policy Framework Act, 2000 (Act No. 5 of 2000).

## 3. FORMULAE FOR PROCUREMENT OF GOODS AND SERVICES

### 3.1. POINTS AWARDED FOR PRICE

#### 3.1.1 THE 90/10 PREFERENCE POINT SYSTEMS

A maximum of 90 points is allocated for price on the following basis:

**90/10**

$$Ps = 90 \left( 1 - \frac{Pt - P_{min}}{P_{min}} \right)$$

Where

- Ps = Points scored for price of tender under consideration
- Pt = Price of tender under consideration
- Pmin = Price of lowest acceptable tender

### 3.2. FORMULAE FOR DISPOSAL OR LEASING OF STATE ASSETS AND INCOME GENERATING PROCUREMENT

#### 3.2.1. POINTS AWARDED FOR PRICE

A maximum of 90 points is allocated for price on the following basis:

**90/10**

$$Ps = 90 \left( 1 + \frac{Pt - P_{max}}{P_{max}} \right)$$

Where

Ps = Points scored for price of tender under consideration

Pt = Price of tender under consideration

Pmax = Price of highest acceptable tender

#### 4. POINTS AWARDED FOR SPECIFIC GOALS

- 4.1. In terms of Regulation 4(2); 5(2); 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded for specific goals stated in the tender. For the purposes of this tender the tenderer will be allocated points based on the goals stated in table 1 below as may be supported by proof/ documentation stated in the conditions of this tender:

**Table 1: Specific goals for the tender and points claimed are indicated per the table below.**

**Note**

- *The 90/10 preference point system is applicable, corresponding points must also be indicated as such.*
- *The tenderer must indicate how they claim points for each preference point system.*

The specific goals allocated points in terms of this tender	Number of points claimable	Number of points claimed. (To be completed by the tenderer)	Percentage ownership equity claimed (To be completed by the tenderer)
HDI: No Franchise	4		
HDI: Women	2		
HDI: People with Disabilities	2		
RDP: The Promotion of South African owned enterprises	2		

#### DECLARATION WITH REGARD TO COMPANY/FIRM

- 4.2. Name of company/firm.....
- 4.3. Company registration number: .....
- 4.4. TYPE OF COMPANY/ FIRM

- ☐ Partnership/Joint Venture / Consortium
- ☐ One-person business/sole propriety
- ☐ Close corporation
- ☐ Public Company
- ☐ Personal Liability Company
- ☐ (Pty) Limited
- ☐ Non-Profit Company
- ☐ State Owned Company

[TICK APPLICABLE BOX]

4.5. I, the undersigned, who is duly authorised to do so on behalf of the company/firm, certify that the points claimed, based on the specific goals as advised in the tender, qualifies the company/ firm for the preference(s) shown and I acknowledge that:

- i) The information furnished is true and correct;
- ii) The preference points claimed are in accordance with the General Conditions as indicated in paragraph 1 of this form;
- iii) In the event of a contract being awarded as a result of points claimed as shown in paragraphs 1.4 and 4.2, the contractor may be required to furnish documentary proof to the satisfaction of the organ of state that the claims are correct;
- iv) If the specific goals have been claimed or obtained on a fraudulent basis or any of the conditions of contract have not been fulfilled, the organ of state may, in addition to any other remedy it may have –
  - (a) disqualify the person from the tendering process;
  - (b) recover costs, losses or damages it has incurred or suffered as a result of that person's conduct;
  - (c) cancel the contract and claim any damages which it has suffered as a result of having to make less favourable arrangements due to such cancellation;
  - (d) recommend that the tenderer or contractor, its shareholders and directors, or only the shareholders and directors who acted on a fraudulent basis, be restricted from obtaining business from any organ of state for a period not exceeding 10 years, after the *audi alteram partem* (hear the other side) rule has been applied; and
  - (e) forward the matter for criminal prosecution, if deemed necessary.

.....  
**SIGNATURE(S) OF TENDERER(S)**

**SURNAME AND NAME:** .....

**DATE:** .....

**ADDRESS:** .....

.....  
.....

## DECLARATION OF COMPLIANCE WITH GOOD MANUFACTURING PRACTICE (GMP)

*To be signed by the Chief Executive Officer (CEO) of the Company in terms of this bid.*

I, .....  
(Full name)

with the following identity number .....

being the Chief Executive Officer (CEO) of .....  
.....  
(Organisation/Company Legal Name)

hereby declares that to the best of my knowledge all reasonable steps have been taken to ensure that:

- a) There are no outstanding or impending GMP or legal matters that may have a material impact on the Company's ability to perform in terms of this contract.
- b) Has complied with all the legal requirements as stipulated in terms of Medicines and Related Substances Act 101 of 1965, as amended, for products offered.
- c) In terms of this declaration, I undertake to inform the Department of Health at first knowledge of any circumstances that may result in interrupted supply.

.....  
Signature CEO                      (Signed at Location)                      (on date)

.....  
Witness Signature                      (Signed at Location)                      (on date)

**This document must be signed and submitted together with your bid**

## **THE NATIONAL INDUSTRIAL PARTICIPATION PROGRAMME**

### **INTRODUCTION**

The National Industrial Participation (NIP) Programme, which is applicable to all government procurement contracts that have an imported content, became effective on the 1 September 1996. The NIP policy and guidelines were fully endorsed by Cabinet on 30 April 1997. In terms of the Cabinet decision, all state and parastatal purchases / lease contracts (for goods, works and services) entered into after this date, are subject to the NIP requirements. NIP is obligatory and therefore must be complied with. The Industrial Participation Secretariat (IPS) of the Department of Trade and Industry (DTI) is charged with the responsibility of administering the programme.

### **1. PILLARS OF THE PROGRAMME**

- 1.1 The NIP obligation is benchmarked on the imported content of the contract. Any contract having an imported content equal to or exceeding US\$ 10 million or other currency equivalent to US\$ 10 million will have a NIP obligation. This threshold of US\$ 10 million can be reached as follows:
  - a) Any single contract with imported content exceeding US\$10 million.
  - b) Multiple contracts for the same goods, works or services each with imported content exceeding US\$3 million awarded to one seller over a 2 year period which in total exceeds US\$10 million.
  - c) A contract with a renewable option clause, where should the option be exercised the total value of the imported content will exceed US\$10 million.
  - d) Multiple suppliers of the same goods, works or services under the same contract, where the value of the imported content of each allocation is equal to or exceeds US\$ 3 million worth of goods, works or services to the same government institution, which in total over a two (2) year period exceeds US\$10 million.
- 1.2 The NIP obligation applicable to suppliers in respect of sub-paragraphs 1.1 (a) to 1.1 (c) above will amount to 30% of the imported content whilst suppliers in respect of paragraph 1.1 (d) shall incur 30% of the total NIP obligation on a *pro-rata* basis.
- 1.3 To satisfy the NIP obligation, the DTI would negotiate and conclude agreements such as investments, joint ventures, sub-contracting, licensee production, export promotion, sourcing arrangements and research and development (R&D) with partners or suppliers.
- 1.4 A period of seven years has been identified as the time frame within which to discharge the obligation.

### **2 REQUIREMENTS OF THE DEPARTMENT OF TRADE AND INDUSTRY**

- 2.1 In order to ensure effective implementation of the programme, successful bidders (contractors) are required to, immediately after the award of a contract that is in excess of R10 million (ten million Rands), submit details of such a contract to the DTI for reporting purposes.
- 2.2 The purpose for reporting details of contracts in excess of the amount of R10 million (ten million Rands) is to cater for multiple contracts for the same goods, works or services; renewable contracts and multiple suppliers for the same goods, works or services under the same contract as provided for in paragraphs 1.1.(b) to 1.1. (d) above.

### 3 BID SUBMISSION AND CONTRACT REPORTING REQUIREMENTS OF BIDDERS AND SUCCESSFUL BIDDERS (CONTRACTORS)

- 3.1 Bidders are required to sign and submit this Standard Bidding Document (SBD 5) together with the bid on the closing date and time.
- 3.2 In order to accommodate multiple contracts for the same goods, works or services; renewable contracts and multiple suppliers for the same goods, works or services under the same contract as indicated in sub-paragraphs 1.1 (b) to 1.1 (d) above and to enable the DTI in determining the NIP obligation, successful bidders (contractors) are required, immediately after being officially notified about any successful bid with a value in excess of R10 million (ten million Rands), to contact and furnish the DTI with the following information:
- Bid/contract number.
  - Description of the goods works or services.
  - Date on which the contract was accepted.
  - Name, address and contact details of the government institution.
  - Value of the contract.
  - Imported content of the contract, if possible.
- 3.3 The information required in paragraph 3.2 above must be sent to the Department of Trade and Industry, Private Bag X84, Pretoria, 0001 for the attention of Mr Elias Malapane within five (5) working days after award of the contract. for further details about the programme, contact Ms R Muthan on telephone (012) 394 1288, Mobile (066) 301 2051 or e-mail at [amuthan@thedtic.gov.za](mailto:amuthan@thedtic.gov.za).

### 4 PROCESS TO SATISFY THE NIP OBLIGATION

- 4.1 Once the successful bidder (contractor) has made contact with and furnished the DTI with the information required, the following steps will be followed:
- a) the contractor and the DTI will determine the NIP obligation;
  - b) the contractor and the DTI will sign the NIP obligation agreement;
  - c) the contractor will submit a performance guarantee to the DTI;
  - d) the contractor will submit a business concept for consideration and approval by the DTI;
  - e) upon approval of the business concept by the DTI, the contractor will submit detailed business plans outlining the business concepts;
  - f) the contractor will implement the business plans; and
  - g) the contractor will submit bi-annual progress reports on approved plans to the DTI.
- 4.2 The NIP obligation agreement is between the DTI and the successful bidder (contractor) and, therefore, does not involve the purchasing institution.

Bid number		Closing date:	
Name of bidder			
Postal Address			
		Postal Code	
Name in print			
Position			
Signature:		Date:	





### AUTHORISATION DECLARATION (PBD1)

NAME OF THE BIDDER

**Are you sourcing the products from a third party?**

Yes

No

*\* If you have answered YES to the above question, please provide full details in the table below of the third party (ies) from whom you are sourcing the products.*

1. Declaration by the bidder where the bidder is sourcing the products from a third party.

The bidder hereby declares the following:-

- 1.1 The bidder is sourcing the products listed in the PBD1.1 attached, from a third party in order to comply with the terms and conditions of the bid.
  - 1.2 The bidder has informed the third party of the terms and conditions of the bid and the third party is acquainted with the said terms and the description of the products listed in the PBD1.1.
  - 1.3 The bidder has received the attached, unconditional written undertaking from the third party to supply the products listed in the PBD1.1 in accordance with the terms and conditions of the bid document for the duration of the contract. A template has been attached (PBD1.2) that is to be used for the purpose of the third party undertaking.
  - 1.4 The bidder confirms that all financial and supply arrangements for the products have been mutually agreed upon between the bidder and the third party.
2. The bidder declares that the information contained herein is true and correct.
  3. The bidder acknowledges that the Department of Health reserves the right to verify the information contained therein and if found to be false or incorrect may invoke any remedies available to it in the bid documents.

Signed at		on the		day of	
Full Names					
Designation					
Signature					

**List of the products offered sourced from third party**

<b>Bid Item No</b>	<b>Brand Name</b>	<b>Name of the company from where the products will be sourced</b>	<b>Address and contact details of the company from where the products will be sourced</b>

**List of the products offered sourced from third party - *continued***

[illegible]

*(Should the table provided not be sufficient for all the items offered, please provide additional information as an attachment and it must be properly referenced to this document)*

**Template for unconditional written undertaking from the third party***Note:**The authorisation letter must be on the official letterhead of the third party**A separate letter must be included for each third party**The authorisation letter must be addressed to the Bidding Company*

Name of Bidding Company: \_\_\_\_\_

Address of Bidding Company: \_\_\_\_\_

\_\_\_\_\_

Attention: \_\_\_\_\_

Dear Sir/Madam

**AUTHORISATION LETTER: CONTRACT NO \_\_\_\_\_**We, \_\_\_\_\_ *(Name of Third Party)*hereby authorise you, \_\_\_\_\_ *(Name of Company)* to include the products listed below in your bid submission for the abovementioned contract.

We confirm that we have firm supply arrangements in place, and have familiarised ourselves with the item descriptions, specifications and bid conditions relating to item/s listed below.

Item no.	Description of product	Brand name

*(Should the table provided not be sufficient for all the items offered, please provide additional information as an attachment and it must be properly referenced to this document)*

Yours faithfully,

\_\_\_\_\_  
Signature of the Third Party:\_\_\_\_\_  
Date:

Definition of fields in Bid Response Document, to be read in conjunction with the Special Requirements and Conditions of Contract	
Field Name	Field Definition
<b>FIELDS WHICH ARE PRE-FILLED AND MAY NOT BE ALTERED</b>	
Item Number	The relevant item number which will be used throughout the contract period. Each item number is linked to a specification
Item Specification	The specification of the item for which a call for bids has been issued, as linked to the item number.
Unit	The unit of measure for the specification. This determines how the estimates are expressed and how the price should be quoted. This may be one injection or one pack of 100 tablets, etc.
Estimate	The estimated quantities associated with the item number and specification, for the full contract period. Estimates are expressed in unit packs.
<b>FIELDS WHICH ARE TO BE COMPLETED BY THE BIDDER FOR ALL ITEMS ON WHICH BIDS ARE OFFERED</b>	
Registered legal name of bidder	The full, registered, legal name of the bidder, as on VAT registration certificate and Medicine Registration Certificate applicant.
Quantity for full period	The volume of the item (expressed in units) which the bidder can provide during the complete period of the tender
Delivered price in ZAR	Final price offered by a bidder for an item number as per specification, which includes VAT and delivery. <b>Must be the price for a unit as advertised.</b>
Registered Product Name	Brand name. Must correspond with Medicine Registration Certificate (1) GW12/7
Conforms to specification?	Confirm whether or not the product on offer conforms exactly to the Item Specification.
If <b>NO</b> : Detail deviation from specification.	Detail exact deviation from Item Specification, as per registration of product on offer.
Product Registration Number	As per Medicine Registration Certificate Certificate(2) GW12/7
License to Manufacture Medicines: License Number , Expiry date	As per License to Manufacture Medicines – this must correspond with the document submitted
Pack Size Offered: Unit pack	Single unit offered according to specification in numbers e.g. each (1) This must correspond with the delivered price.
Pack Size Offered: Shelf Pack	Number of Unit Packs within the smallest wrap (e.g. 10 ampoules)
Standard units in: Shipper Pack	Number of unit packs in a shipper / bulk box
Lead-Time	Interval between receipt of an order until delivery at facility which placed the order. Must not exceed 14 calendar days.
Initial lead time	Interval between award of the tender and ability to fill an order. This must not exceed 75 calendar days.
Minimum Order Quantity	The lowest acceptable quantity for a given purchase order.
Batch size for the bid item, in number of packs	Batch size, expressed in number of units
Monthly batch capacity	Monthly batch capacity that will be assigned for the bid item for the duration of the contract expressed in number of batches.
Technical amendment required?	Do you require a technical amendment to perform according to the conditions of your bid Y/N
If YES: Provide details	Provide all relevant details (can be provided in a covering letter)

Definition of fields in Bid Response Document, to be read in conjunction with the Special Requirements and Conditions of Contract	
Field Name	Field Definition
EAN 13 Barcode for Unit Pack	Provide Number
EAN 13 Barcode for Shelf Pack	Provide Number
ITF14 Barcode for Shipper Pack	Provide Number
2D Barcode or Similar	Provide Number
NAPPI Code	Provide Code
Manufacturer	As per MCC Certificate (8) GW12/7 – List all sources
SEP Price	The most recently approved Single Exit Price expressed in corresponding unit to bid
Are any of the listed manufacturers etc. 3rd parties to the bidder?	Y/N <b>If YES - complete PBD1 and include letter(s) of authorisation as applicable</b>
API Source Full Site Name (x3)	Full name of API source, including company name and site – List all sources
API Source Full Address	Full physical address of API source – List all sources
API Source Country	Country of API source – List all sources
API Source Contact	Listed contact information
PRICING COMPONENT BREAKDOWN	
Note: VAT must be apportioned equally across all components. Please see pricing section in Special Conditions	
Percentage of Delivered Price attributable to API	The percentage of the Delivered Price associated with API, (the therapeutically active component of the medicine). Should an item be imported as finished product, the component may be reflected as part of formulation cost.
Imported (API)	Portion of API component attributable to imported expenditure
Percentage of Delivered Price attributable to Formulation	The percentage of the delivered price associated with Formulation, (includes all operations in the process of which different chemical substances, including the API, are combined to produce a final medicinal product), includes material, processing, production, quality assurance and related controls.
Local (Formulation)	Portion of Formulation component attributable to local expenditure
Imported (Formulation)	Portion of Formulation component attributable to imported expenditure
Packaging	The percentage of the Delivered Price associated with Packaging, where packaging includes all operations in the process of packaging medicine into primary and/or secondary packaging, packaging material and labels.
Local (Packaging)	Portion of Packaging component attributable to local expenditure
Imported (Packaging)	Portion of Packaging component attributable to imported expenditure
Logistics	Percentage of delivered price associated with logistics, where logistics includes all operations, taking place within the Republic of South Africa, relating to the storage, distribution and transportation of medicine to the healthcare facility or pharmaceutical depot.
Gross Margin	Percentage of delivered price not associated with API, Formulation, Packaging, or Logistics.
Currency	Primary currency in which manufacturer trades for imported components

# THE NATIONAL TREASURY

Republic of South Africa



---

## GOVERNMENT PROCUREMENT: GENERAL CONDITIONS OF CONTRACT

July 2010

# **GOVERNMENT PROCUREMENT**

## **GENERAL CONDITIONS OF CONTRACT**

### **July 2010**

#### **NOTES**

The purpose of this document is to:

- (i) Draw special attention to certain general conditions applicable to government bids, contracts and orders; and
- (ii) To ensure that clients be familiar with regard to the rights and obligations of all parties involved in doing business with government.

In this document words in the singular also mean in the plural and vice versa and words in the masculine also mean in the feminine and neuter.

- The General Conditions of Contract will form part of all bid documents and may not be amended.
- Special Conditions of Contract (SCC) relevant to a specific bid, should be compiled separately for every bid (if applicable) and will supplement the General Conditions of Contract. Whenever there is a conflict, the provisions in the SCC shall prevail.



## TABLE OF CLAUSES

1. Definitions
2. Application
3. General
4. Standards
5. Use of contract documents and information; inspection
6. Patent rights
7. Performance security
8. Inspections, tests and analysis
9. Packing
10. Delivery and documents
11. Insurance
12. Transportation
13. Incidental services
14. Spare parts
15. Warranty
16. Payment
17. Prices
18. Contract amendments
19. Assignment
20. Subcontracts
21. Delays in the supplier's performance
22. Penalties
23. Termination for default
24. Dumping and countervailing duties
25. Force Majeure
26. Termination for insolvency
27. Settlement of disputes
28. Limitation of liability
29. Governing language
30. Applicable law
31. Notices
32. Taxes and duties
33. National Industrial Participation Programme (NIPP)
34. Prohibition of restrictive practices

## General Conditions of Contract

### 1. Definitions

1. The following terms shall be interpreted as indicated:
  - 1.1 “Closing time” means the date and hour specified in the bidding documents for the receipt of bids.
  - 1.2 “Contract” means the written agreement entered into between the purchaser and the supplier, as recorded in the contract form signed by the parties, including all attachments and appendices thereto and all documents incorporated by reference therein.
  - 1.3 “Contract price” means the price payable to the supplier under the contract for the full and proper performance of his contractual obligations.
  - 1.4 “Corrupt practice” means the offering, giving, receiving, or soliciting of any thing of value to influence the action of a public official in the procurement process or in contract execution.
  - 1.5 "Countervailing duties" are imposed in cases where an enterprise abroad is subsidized by its government and encouraged to market its products internationally.
  - 1.6 “Country of origin” means the place where the goods were mined, grown or produced or from which the services are supplied. Goods are produced when, through manufacturing, processing or substantial and major assembly of components, a commercially recognized new product results that is substantially different in basic characteristics or in purpose or utility from its components.
  - 1.7 “Day” means calendar day.
  - 1.8 “Delivery” means delivery in compliance of the conditions of the contract or order.
  - 1.9 “Delivery ex stock” means immediate delivery directly from stock actually on hand.
  - 1.10 “Delivery into consignees store or to his site” means delivered and unloaded in the specified store or depot or on the specified site in compliance with the conditions of the contract or order, the supplier bearing all risks and charges involved until the supplies are so delivered and a valid receipt is obtained.
  - 1.11 "Dumping" occurs when a private enterprise abroad market its goods on own initiative in the RSA at lower prices than that of the country of origin and which have the potential to harm the local industries in the

RSA.

- 1.12 "Force majeure" means an event beyond the control of the supplier and not involving the supplier's fault or negligence and not foreseeable. Such events may include, but is not restricted to, acts of the purchaser in its sovereign capacity, wars or revolutions, fires, floods, epidemics, quarantine restrictions and freight embargoes.
- 1.13 "Fraudulent practice" means a misrepresentation of facts in order to influence a procurement process or the execution of a contract to the detriment of any bidder, and includes collusive practice among bidders (prior to or after bid submission) designed to establish bid prices at artificial non-competitive levels and to deprive the bidder of the benefits of free and open competition.
- 1.14 "GCC" means the General Conditions of Contract.
- 1.15 "Goods" means all of the equipment, machinery, and/or other materials that the supplier is required to supply to the purchaser under the contract.
- 1.16 "Imported content" means that portion of the bidding price represented by the cost of components, parts or materials which have been or are still to be imported (whether by the supplier or his subcontractors) and which costs are inclusive of the costs abroad, plus freight and other direct importation costs such as landing costs, dock dues, import duty, sales duty or other similar tax or duty at the South African place of entry as well as transportation and handling charges to the factory in the Republic where the supplies covered by the bid will be manufactured.
- 1.17 "Local content" means that portion of the bidding price which is not included in the imported content provided that local manufacture does take place.
- 1.18 "Manufacture" means the production of products in a factory using labour, materials, components and machinery and includes other related value-adding activities.
- 1.19 "Order" means an official written order issued for the supply of goods or works or the rendering of a service.
- 1.20 "Project site," where applicable, means the place indicated in bidding documents.
- 1.21 "Purchaser" means the organization purchasing the goods.
- 1.22 "Republic" means the Republic of South Africa.
- 1.23 "SCC" means the Special Conditions of Contract.
- 1.24 "Services" means those functional services ancillary to the supply of the goods, such as transportation and any other incidental services, such as installation, commissioning, provision of technical assistance, training, catering, gardening, security, maintenance and other such

obligations of the supplier covered under the contract.

- 1.25 “Written” or “in writing” means handwritten in ink or any form of electronic or mechanical writing.

## **2. Application**

- 2.1 These general conditions are applicable to all bids, contracts and orders including bids for functional and professional services, sales, hiring, letting and the granting or acquiring of rights, but excluding immovable property, unless otherwise indicated in the bidding documents.
- 2.2 Where applicable, special conditions of contract are also laid down to cover specific supplies, services or works.
- 2.3 Where such special conditions of contract are in conflict with these general conditions, the special conditions shall apply.

## **3. General**

- 3.1 Unless otherwise indicated in the bidding documents, the purchaser shall not be liable for any expense incurred in the preparation and submission of a bid. Where applicable a non-refundable fee for documents may be charged.
- 3.2 With certain exceptions, invitations to bid are only published in the Government Tender Bulletin. The Government Tender Bulletin may be obtained directly from the Government Printer, Private Bag X85, Pretoria 0001, or accessed electronically from [www.treasury.gov.za](http://www.treasury.gov.za)

## **4. Standards**

- 4.1 The goods supplied shall conform to the standards mentioned in the bidding documents and specifications.

## **5. Use of contract documents and information; inspection.**

- 5.1 The supplier shall not, without the purchaser’s prior written consent, disclose the contract, or any provision thereof, or any specification, plan, drawing, pattern, sample, or information furnished by or on behalf of the purchaser in connection therewith, to any person other than a person employed by the supplier in the performance of the contract. Disclosure to any such employed person shall be made in confidence and shall extend only so far as may be necessary for purposes of such performance.
- 5.2 The supplier shall not, without the purchaser’s prior written consent, make use of any document or information mentioned in GCC clause 5.1 except for purposes of performing the contract.
- 5.3 Any document, other than the contract itself mentioned in GCC clause 5.1 shall remain the property of the purchaser and shall be returned (all copies) to the purchaser on completion of the supplier’s performance under the contract if so required by the purchaser.
- 5.4 The supplier shall permit the purchaser to inspect the supplier’s records relating to the performance of the supplier and to have them audited by auditors appointed by the purchaser, if so required by the purchaser.

## **6. Patent rights**

- 6.1 The supplier shall indemnify the purchaser against all third-party claims of infringement of patent, trademark, or industrial design rights arising from use of the goods or any part thereof by the purchaser.

**7. Performance security**

- 7.1 Within thirty (30) days of receipt of the notification of contract award, the successful bidder shall furnish to the purchaser the performance security of the amount specified in SCC.
- 7.2 The proceeds of the performance security shall be payable to the purchaser as compensation for any loss resulting from the supplier's failure to complete his obligations under the contract.
- 7.3 The performance security shall be denominated in the currency of the contract, or in a freely convertible currency acceptable to the purchaser and shall be in one of the following forms:
- (a) a bank guarantee or an irrevocable letter of credit issued by a reputable bank located in the purchaser's country or abroad, acceptable to the purchaser, in the form provided in the bidding documents or another form acceptable to the purchaser; or
  - (b) a cashier's or certified cheque
- 7.4 The performance security will be discharged by the purchaser and returned to the supplier not later than thirty (30) days following the date of completion of the supplier's performance obligations under the contract, including any warranty obligations, unless otherwise specified in SCC.

**8. Inspections, tests and analyses**

- 8.1 All pre-bidding testing will be for the account of the bidder.
- 8.2 If it is a bid condition that supplies to be produced or services to be rendered should at any stage during production or execution or on completion be subject to inspection, the premises of the bidder or contractor shall be open, at all reasonable hours, for inspection by a representative of the Department or an organization acting on behalf of the Department.
- 8.3 If there are no inspection requirements indicated in the bidding documents and no mention is made in the contract, but during the contract period it is decided that inspections shall be carried out, the purchaser shall itself make the necessary arrangements, including payment arrangements with the testing authority concerned.
- 8.4 If the inspections, tests and analyses referred to in clauses 8.2 and 8.3 show the supplies to be in accordance with the contract requirements, the cost of the inspections, tests and analyses shall be defrayed by the purchaser.
- 8.5 Where the supplies or services referred to in clauses 8.2 and 8.3 do not comply with the contract requirements, irrespective of whether such supplies or services are accepted or not, the cost in connection with these inspections, tests or analyses shall be defrayed by the supplier.
- 8.6 Supplies and services which are referred to in clauses 8.2 and 8.3 and which do not comply with the contract requirements may be rejected.
- 8.7 Any contract supplies may on or after delivery be inspected, tested or

analyzed and may be rejected if found not to comply with the requirements of the contract. Such rejected supplies shall be held at the cost and risk of the supplier who shall, when called upon, remove them immediately at his own cost and forthwith substitute them with supplies which do comply with the requirements of the contract. Failing such removal the rejected supplies shall be returned at the suppliers cost and risk. Should the supplier fail to provide the substitute supplies forthwith, the purchaser may, without giving the supplier further opportunity to substitute the rejected supplies, purchase such supplies as may be necessary at the expense of the supplier.

- 8.8 The provisions of clauses 8.4 to 8.7 shall not prejudice the right of the purchaser to cancel the contract on account of a breach of the conditions thereof, or to act in terms of Clause 23 of GCC.

## **9. Packing**

- 9.1 The supplier shall provide such packing of the goods as is required to prevent their damage or deterioration during transit to their final destination, as indicated in the contract. The packing shall be sufficient to withstand, without limitation, rough handling during transit and exposure to extreme temperatures, salt and precipitation during transit, and open storage. Packing, case size and weights shall take into consideration, where appropriate, the remoteness of the goods' final destination and the absence of heavy handling facilities at all points in transit.
- 9.2 The packing, marking, and documentation within and outside the packages shall comply strictly with such special requirements as shall be expressly provided for in the contract, including additional requirements, if any, specified in SCC, and in any subsequent instructions ordered by the purchaser.

## **10. Delivery and documents**

- 10.1 Delivery of the goods shall be made by the supplier in accordance with the terms specified in the contract. The details of shipping and/or other documents to be furnished by the supplier are specified in SCC.
- 10.2 Documents to be submitted by the supplier are specified in SCC.

## **11. Insurance**

- 11.1 The goods supplied under the contract shall be fully insured in a freely convertible currency against loss or damage incidental to manufacture or acquisition, transportation, storage and delivery in the manner specified in the SCC.

## **12. Transportation**

- 12.1 Should a price other than an all-inclusive delivered price be required, this shall be specified in the SCC.

## **13. Incidental services**

- 13.1 The supplier may be required to provide any or all of the following services, including additional services, if any, specified in SCC:
- (a) performance or supervision of on-site assembly and/or commissioning of the supplied goods;
  - (b) furnishing of tools required for assembly and/or maintenance of the supplied goods;
  - (c) furnishing of a detailed operations and maintenance manual for each appropriate unit of the supplied goods;

- (d) performance or supervision or maintenance and/or repair of the supplied goods, for a period of time agreed by the parties, provided that this service shall not relieve the supplier of any warranty obligations under this contract; and
- (e) training of the purchaser's personnel, at the supplier's plant and/or on-site, in assembly, start-up, operation, maintenance, and/or repair of the supplied goods.

13.2 Prices charged by the supplier for incidental services, if not included in the contract price for the goods, shall be agreed upon in advance by the parties and shall not exceed the prevailing rates charged to other parties by the supplier for similar services.

#### **14. Spare parts**

14.1 As specified in SCC, the supplier may be required to provide any or all of the following materials, notifications, and information pertaining to spare parts manufactured or distributed by the supplier:

- (a) such spare parts as the purchaser may elect to purchase from the supplier, provided that this election shall not relieve the supplier of any warranty obligations under the contract; and
- (b) in the event of termination of production of the spare parts:
  - (i) Advance notification to the purchaser of the pending termination, in sufficient time to permit the purchaser to procure needed requirements; and
  - (ii) following such termination, furnishing at no cost to the purchaser, the blueprints, drawings, and specifications of the spare parts, if requested.

#### **15. Warranty**

15.1 The supplier warrants that the goods supplied under the contract are new, unused, of the most recent or current models, and that they incorporate all recent improvements in design and materials unless provided otherwise in the contract. The supplier further warrants that all goods supplied under this contract shall have no defect, arising from design, materials, or workmanship (except when the design and/or material is required by the purchaser's specifications) or from any act or omission of the supplier, that may develop under normal use of the supplied goods in the conditions prevailing in the country of final destination.

15.2 This warranty shall remain valid for twelve (12) months after the goods, or any portion thereof as the case may be, have been delivered to and accepted at the final destination indicated in the contract, or for eighteen (18) months after the date of shipment from the port or place of loading in the source country, whichever period concludes earlier, unless specified otherwise in SCC.

15.3 The purchaser shall promptly notify the supplier in writing of any claims arising under this warranty.

15.4 Upon receipt of such notice, the supplier shall, within the period specified in SCC and with all reasonable speed, repair or replace the defective goods or parts thereof, without costs to the purchaser.

15.5 If the supplier, having been notified, fails to remedy the defect(s) within the period specified in SCC, the purchaser may proceed to take

such remedial action as may be necessary, at the supplier's risk and expense and without prejudice to any other rights which the purchaser may have against the supplier under the contract.

**16. Payment**

- 16.1 The method and conditions of payment to be made to the supplier under this contract shall be specified in SCC.
- 16.2 The supplier shall furnish the purchaser with an invoice accompanied by a copy of the delivery note and upon fulfillment of other obligations stipulated in the contract.
- 16.3 Payments shall be made promptly by the purchaser, but in no case later than thirty (30) days after submission of an invoice or claim by the supplier.
- 16.4 Payment will be made in Rand unless otherwise stipulated in SCC.

**17. Prices**

- 17.1 Prices charged by the supplier for goods delivered and services performed under the contract shall not vary from the prices quoted by the supplier in his bid, with the exception of any price adjustments authorized in SCC or in the purchaser's request for bid validity extension, as the case may be.

**18. Contract amendments**

- 18.1 No variation in or modification of the terms of the contract shall be made except by written amendment signed by the parties concerned.

**19. Assignment**

- 19.1 The supplier shall not assign, in whole or in part, its obligations to perform under the contract, except with the purchaser's prior written consent.

**20. Subcontracts**

- 20.1 The supplier shall notify the purchaser in writing of all subcontracts awarded under this contracts if not already specified in the bid. Such notification, in the original bid or later, shall not relieve the supplier from any liability or obligation under the contract.

**21. Delays in the supplier's performance**

- 21.1 Delivery of the goods and performance of services shall be made by the supplier in accordance with the time schedule prescribed by the purchaser in the contract.
- 21.2 If at any time during performance of the contract, the supplier or its subcontractor(s) should encounter conditions impeding timely delivery of the goods and performance of services, the supplier shall promptly notify the purchaser in writing of the fact of the delay, its likely duration and its cause(s). As soon as practicable after receipt of the supplier's notice, the purchaser shall evaluate the situation and may at his discretion extend the supplier's time for performance, with or without the imposition of penalties, in which case the extension shall be ratified by the parties by amendment of contract.
- 21.3 No provision in a contract shall be deemed to prohibit the obtaining of supplies or services from a national department, provincial department, or a local authority.
- 21.4 The right is reserved to procure outside of the contract small quantities or to have minor essential services executed if an emergency arises, the



supplier's point of supply is not situated at or near the place where the supplies are required, or the supplier's services are not readily available.

21.5 Except as provided under GCC Clause 25, a delay by the supplier in the performance of its delivery obligations shall render the supplier liable to the imposition of penalties, pursuant to GCC Clause 22, unless an extension of time is agreed upon pursuant to GCC Clause 21.2 without the application of penalties.

21.6 Upon any delay beyond the delivery period in the case of a supplies contract, the purchaser shall, without canceling the contract, be entitled to purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract and to return any goods delivered later at the supplier's expense and risk, or to cancel the contract and buy such goods as may be required to complete the contract and without prejudice to his other rights, be entitled to claim damages from the supplier.

## **22. Penalties**

22.1 Subject to GCC Clause 25, if the supplier fails to deliver any or all of the goods or to perform the services within the period(s) specified in the contract, the purchaser shall, without prejudice to its other remedies under the contract, deduct from the contract price, as a penalty, a sum calculated on the delivered price of the delayed goods or unperformed services using the current prime interest rate calculated for each day of the delay until actual delivery or performance. The purchaser may also consider termination of the contract pursuant to GCC Clause 23.

## **23. Termination for default**

23.1 The purchaser, without prejudice to any other remedy for breach of contract, by written notice of default sent to the supplier, may terminate this contract in whole or in part:

- (a) if the supplier fails to deliver any or all of the goods within the period(s) specified in the contract, or within any extension thereof granted by the purchaser pursuant to GCC Clause 21.2;
- (b) if the Supplier fails to perform any other obligation(s) under the contract; or
- (c) if the supplier, in the judgment of the purchaser, has engaged in corrupt or fraudulent practices in competing for or in executing the contract.

23.2 In the event the purchaser terminates the contract in whole or in part, the purchaser may procure, upon such terms and in such manner as it deems appropriate, goods, works or services similar to those undelivered, and the supplier shall be liable to the purchaser for any excess costs for such similar goods, works or services. However, the supplier shall continue performance of the contract to the extent not terminated.

23.3 Where the purchaser terminates the contract in whole or in part, the purchaser may decide to impose a restriction penalty on the supplier by prohibiting such supplier from doing business with the public sector for a period not exceeding 10 years.

23.4 If a purchaser intends imposing a restriction on a supplier or any

person associated with the supplier, the supplier will be allowed a time period of not more than fourteen (14) days to provide reasons why the envisaged restriction should not be imposed. Should the supplier fail to respond within the stipulated fourteen (14) days the purchaser may regard the intended penalty as not objected against and may impose it on the supplier.

23.5 Any restriction imposed on any person by the Accounting Officer / Authority will, at the discretion of the Accounting Officer / Authority, also be applicable to any other enterprise or any partner, manager, director or other person who wholly or partly exercises or exercised or may exercise control over the enterprise of the first-mentioned person, and with which enterprise or person the first-mentioned person, is or was in the opinion of the Accounting Officer / Authority actively associated.

23.6 If a restriction is imposed, the purchaser must, within five (5) working days of such imposition, furnish the National Treasury, with the following information:

- (i) the name and address of the supplier and / or person restricted by the purchaser;
- (ii) the date of commencement of the restriction
- (iii) the period of restriction; and
- (iv) the reasons for the restriction.

These details will be loaded in the National Treasury's central database of suppliers or persons prohibited from doing business with the public sector.

23.7 If a court of law convicts a person of an offence as contemplated in sections 12 or 13 of the Prevention and Combating of Corrupt Activities Act, No. 12 of 2004, the court may also rule that such person's name be endorsed on the Register for Tender Defaulters. When a person's name has been endorsed on the Register, the person will be prohibited from doing business with the public sector for a period not less than five years and not more than 10 years. The National Treasury is empowered to determine the period of restriction and each case will be dealt with on its own merits. According to section 32 of the Act the Register must be open to the public. The Register can be perused on the National Treasury website.

#### **24. Anti-dumping and countervailing duties and rights**

24.1 When, after the date of bid, provisional payments are required, or anti-dumping or countervailing duties are imposed, or the amount of a provisional payment or anti-dumping or countervailing right is increased in respect of any dumped or subsidized import, the State is not liable for any amount so required or imposed, or for the amount of any such increase. When, after the said date, such a provisional payment is no longer required or any such anti-dumping or countervailing right is abolished, or where the amount of such provisional payment or any such right is reduced, any such favourable difference shall on demand be paid forthwith by the contractor to the State or the State may deduct such amounts from moneys (if any) which may otherwise be due to the contractor in regard to supplies or services which he delivered or rendered, or is to deliver or render in terms of the contract or any other contract or any other amount which

may be due to him

**25. Force Majeure**

- 25.1 Notwithstanding the provisions of GCC Clauses 22 and 23, the supplier shall not be liable for forfeiture of its performance security, damages, or termination for default if and to the extent that his delay in performance or other failure to perform his obligations under the contract is the result of an event of force majeure.
- 25.2 If a force majeure situation arises, the supplier shall promptly notify the purchaser in writing of such condition and the cause thereof. Unless otherwise directed by the purchaser in writing, the supplier shall continue to perform its obligations under the contract as far as is reasonably practical, and shall seek all reasonable alternative means for performance not prevented by the force majeure event.

**26. Termination for insolvency**

- 26.1 The purchaser may at any time terminate the contract by giving written notice to the supplier if the supplier becomes bankrupt or otherwise insolvent. In this event, termination will be without compensation to the supplier, provided that such termination will not prejudice or affect any right of action or remedy which has accrued or will accrue thereafter to the purchaser.

**27. Settlement of Disputes**

- 27.1 If any dispute or difference of any kind whatsoever arises between the purchaser and the supplier in connection with or arising out of the contract, the parties shall make every effort to resolve amicably such dispute or difference by mutual consultation.
- 27.2 If, after thirty (30) days, the parties have failed to resolve their dispute or difference by such mutual consultation, then either the purchaser or the supplier may give notice to the other party of his intention to commence with mediation. No mediation in respect of this matter may be commenced unless such notice is given to the other party.
- 27.3 Should it not be possible to settle a dispute by means of mediation, it may be settled in a South African court of law.
- 27.4 Mediation proceedings shall be conducted in accordance with the rules of procedure specified in the SCC.
- 27.5 Notwithstanding any reference to mediation and/or court proceedings herein,
- (a) the parties shall continue to perform their respective obligations under the contract unless they otherwise agree; and
  - (b) the purchaser shall pay the supplier any monies due the supplier.

**28. Limitation of liability**

- 28.1 Except in cases of criminal negligence or willful misconduct, and in the case of infringement pursuant to Clause 6;
- (a) the supplier shall not be liable to the purchaser, whether in contract, tort, or otherwise, for any indirect or consequential loss or damage, loss of use, loss of production, or loss of profits or interest costs, provided that this exclusion shall not apply to any obligation of the supplier to pay penalties and/or damages to the purchaser; and

- (b) the aggregate liability of the supplier to the purchaser, whether under the contract, in tort or otherwise, shall not exceed the total contract price, provided that this limitation shall not apply to the cost of repairing or replacing defective equipment.
- 29. Governing language** 29.1 The contract shall be written in English. All correspondence and other documents pertaining to the contract that is exchanged by the parties shall also be written in English.
- 30. Applicable law** 30.1 The contract shall be interpreted in accordance with South African laws, unless otherwise specified in SCC.
- 31. Notices** 31.1 Every written acceptance of a bid shall be posted to the supplier concerned by registered or certified mail and any other notice to him shall be posted by ordinary mail to the address furnished in his bid or to the address notified later by him in writing and such posting shall be deemed to be proper service of such notice
- 31.2 The time mentioned in the contract documents for performing any act after such aforesaid notice has been given, shall be reckoned from the date of posting of such notice.
- 32. Taxes and duties** 32.1 A foreign supplier shall be entirely responsible for all taxes, stamp duties, license fees, and other such levies imposed outside the purchaser's country.
- 32.2 A local supplier shall be entirely responsible for all taxes, duties, license fees, etc., incurred until delivery of the contracted goods to the purchaser.
- 32.3 No contract shall be concluded with any bidder whose tax matters are not in order. Prior to the award of a bid the Department must be in possession of a tax clearance certificate, submitted by the bidder. This certificate must be an original issued by the South African Revenue Services.
- 33. National Industrial Participation Programme (NIP)** 33.1 The NIP Programme administered by the Department of Trade and Industry shall be applicable to all contracts that are subject to the NIP obligation.
- 34 Prohibition of Restrictive practices** In terms of section 4 (1) (b) (iii) of the Competition Act No. 89 of 1998, as amended, an agreement between, or concerted practice by, firms, or a decision by an association of firms, is prohibited if it is between parties in a horizontal relationship and if a bidder (s) is / are or a contractor(s) was / were involved in collusive bidding (or bid rigging).
- 34.2 If a bidder(s) or contractor(s), based on reasonable grounds or evidence obtained by the purchaser, has / have engaged in the restrictive practice referred to above, the purchaser may refer the matter to the Competition Commission for investigation and possible imposition of administrative penalties as contemplated in the Competition Act No. 89 of 1998.
- 34.3 If a bidder(s) or contractor(s), has / have been found guilty by the Competition Commission of the restrictive practice referred to above, the purchaser may, in addition and without prejudice to any other remedy provided for, invalidate the bid(s) for such item(s) offered, and / or

terminate the contract in whole or part, and / or restrict the bidder(s) or contractor(s) from conducting business with the public sector for a period not exceeding ten (10) years and / or claim damages from the bidder(s) or contractor(s) concerned.

Js General Conditions of Contract (revised July 2010)



## **SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT**

---

**HP09-2026SD**

**SUPPLY AND DELIVERY OF SOLID DOSAGE FORMS TO THE DEPARTMENT OF HEALTH  
FOR THE PERIOD 01 MAY 2026 TO 30 APRIL 2029**

**BID VALIDITY PERIOD: 180 DAYS**

**BID ADVERT DATE: 6 JUNE 2025**

**CLOSING DATE AND TIME OF BID:  
4 AUGUST 2025 AT 11H00**

**NON-COMPULSORY ONLINE BRIEFING SESSION:**

**MS TEAMS WEBINAR: 20 JUNE 2025 @ 10H00**



## Special Requirements and Conditions of Contract HP09-2026SD

*Table of Contents*

1. ABBREVIATIONS .....	5
2. DEFINITIONS .....	6
SECTION A .....	12
3. BID DOCUMENT CHECK LIST .....	12
3.1.1. LEGISLATIVE AND REGULATORY FRAMEWORK .....	18
3.1.2. BID INFORMATION SESSION .....	18
3.1.3. EVALUATION CRITERIA .....	19
4. PHASE I: ADMINISTRATIVE EVALUATION .....	19
4.1. BID DOCUMENTS .....	20
4.2. CONSORTIUMS, JOINT VENTURE (INCORPORATED OR UNINCORPORATED), AND PARTNERSHIPS .....	21
4.3. TAX COMPLIANCE STATUS .....	23
5. PHASE II: PRODUCT TECHNICAL EVALUATION: LEGAL AND REGULATORY .....	24
5.1. LEGISLATIVE REQUIREMENTS RELATING TO THIS BID .....	24
5.1.1 LICENSING REQUIREMENTS .....	24
5.1.2 MEDICINE REGISTRATION CERTIFICATE (MRC) REQUIREMENTS AND VARIATION SUMMARIES .....	26
5.1.4 AUTHORISATION DECLARATION (PBD1.2) .....	27
5.1.5 SAMPLES TO BE SUBMITTED TO SAMPLE EVALUATION SITES .....	27
5.1.6 COMPLIANCE WITH SPECIFICATIONS .....	29
6. PHASE III: PRICE AND PREFERENCE POINTS EVALUATION .....	29
6.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS CLAIMED IN TERMS OF THE REVISED PREFERENTIAL PROCUREMENT REGULATIONS (PPPFA), 2022 .....	29
6.1.1. HDI AND RDP GOAL POINTS CLAIMABLE FOR THIS TENDER .....	30
6.1.2. HDI CLAIMS MADE IN SBD 6.1 MUST BE SUPPORTED BY EVIDENCE BASED DOCUMENTATION .....	30
6.1.2.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS FOR HDI. ....	31
6.1.3. RDP GOAL: PROMOTION OF SOUTH AFRICAN OWNED ENTERPRISES .....	33
6.1.3.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS .....	33
6.1.4. POINTS CLAIMABLE .....	33
6.2. HDI CLAIMS IN CONSORTIUMS, UNINCORPORATED JOINT VENTURES AND PARTNERSHIPS .....	34
6.2.1. FORMULAE - PREFERENCE POINT SYSTEM TO BE APPLIED IN THIS TENDER .....	35
6.2.2. FORMULA FOR PRICE (90) .....	35
6.2.3. FORMULA FOR HDI PREFERENCE POINTS (10) .....	36
7. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS .....	36
8. VALUE ADDED TAX .....	37



## Special Requirements and Conditions of Contract HP09-2026SD

9. SUBMISSION OF BIDS .....	37
10. COMPLETION OF DOCUMENTS AND BID SUBMISSION .....	38
11. LATE BIDS.....	41
12. COUNTER CONDITIONS.....	41
13. FRONTING .....	41
14. SUPPLIER DUE DILIGENCE .....	42
15. COMMUNICATION .....	42
16. CONTACT DETAILS.....	43
SECTION B .....	44
17. CONTRACT PERIOD .....	44
18. PARTICIPATING AUTHORITIES .....	44
19. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES .....	45
20. AWARD CONDITIONS .....	45
20.1. SPLIT AND MULTIPLE AWARDS.....	46
20.2. THERAPEUTIC CLASS AWARDS.....	47
20.3. SERIES AWARDS .....	55
20.4. PROCUREMENT CLASS .....	57
20.5. REFERENCE PRICING.....	57
20.6. NEGOTIATIONS .....	58
20.7. NON-COMMITMENT.....	58
21. POST AWARD CONDITIONS .....	59
22. PRICE REVIEW.....	59
22.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS .....	60
22.2. INSTRUCTIONS FOR PRICE BREAKDOWN .....	60
22.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK .....	61
22.4. APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS.....	62
22.4.1. EXCEPTIONAL PRICE ADJUSTMENTS BEFORE START OF CONTRACT .....	63
22.4.2. ROUTINE PRICE ADJUSTMENTS .....	63
22.4.3. EXCEPTIONAL PRICE ADJUSTMENTS DURING CONTRACT PERIOD .....	64
22.5. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW .....	65
23. QUALITY.....	65
24. DELIVERY AND QUANTITIES .....	65
24.1. DELIVERY BASIS.....	65
24.2. QUANTITIES .....	66
SECTION C .....	67
25. SUPPLIER PERFORMANCE MANAGEMENT.....	67
25.1. COMPLIANCE WITH REPORTING REQUIREMENTS: .....	67
25.3 ORDER PLACEMENT AND DELIVERY:.....	68
25.4 ORDER CANCELLATIONS AND SUBSTITUTION:.....	69
25.5 IRRATIONAL OR MISALIGNED ORDERS: .....	69





## Special Requirements and Conditions of Contract HP09-2026SD

<b>25.6 DELIVERY ADHERENCE</b>	69
<b>25.7 CONTINUITY OF SUPPLY</b>	70
26. REPORTING	73
27. PACKAGING, LABELLING AND BARCODES	73
<b>27.1. PACKAGING</b>	73
<b>27.2. LABELLING</b>	74
<b>27.3. BARCODES</b>	75
28. SHELF LIFE	75
29. DISCONTINUATION OF CONTRACTED PRODUCT SUPPLY	76
30. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS	77
31. CANCELLATION OF CONTRACT	77
32. THIRD PARTIES	77



## Special Requirements and Conditions of Contract HP09-2026SD

## 1. ABBREVIATIONS

API	:Active Pharmaceutical Ingredient
BAC	:Bid Adjudication Committee
BAU	:Business as Usual
CPA	:Contract Price Adjustment
CIPC	:Companies and Intellectual Property Commission
CSD	:Central Supplier Data base
DVP	:Digital Variation Portal
EAN	:European Article Numbering
EU	:European Union
GMP	:Good Manufacturing Practice
HDI	:Historically Disadvantaged Individual
ID	:Identification Document
IVD	:In vitro diagnostic
MCC	:Medicines Control Council
MHPL	:Master Health Products List
MRC	:Medicine Registration Certificate
NDoH	:National Department of Health
PBD	:Pharmaceutical Bidding Documents
PI	:Package Insert
PPPFA	:Preferential Procurement Policy Framework Act
RoE	:Rate of Exchange
RDP	:Reconstruction and Development Programme
SAHPRA	:South African Health Products Regulatory Authority
SARS	:South African Revenue Service
SBD	:Standard Bidding Document
SEP	:Single Exit Price
SRCC	:Special Requirements Conditions of Contract
VAT	:Value Added Tax



## 2. DEFINITIONS

Unless otherwise specified in this SRCC, any word or expression defined in the applicable Act retains the same meaning within this document, where -

- (1) "Complementary medicine" means any substance or mixture of substances that-
  - (a) originates from plants, fungi, algae, seaweeds, lichens, minerals, animals or other substance as determined by SAHPRA.
  - (b) is used or purporting to be suitable for use or manufactured or sold for use
    - (i) in maintaining, complementing or assisting the physical or mental state; or
    - (ii) to diagnose, treat, mitigate, modify, alleviate or prevent disease or illness or the symptoms or signs thereof or abnormal physical or mental state of a human being or animal; and
  - (c) is used-
    - (i) as a health supplement; or
    - (ii) in accordance with those disciplines as determined by SAHPRA.
- (2) "Consortium" means a contractual collaboration between two or more separate legal entities who combine resources or expertise for a specific tender or project, without forming a new legal entity.
- (3) "Contract" means the agreement that results from the acceptance of a tender.
- (4) "Disability" means, in respect of a person, a permanent impairment of a physical, intellectual, or sensory function, which results in restricted, or lack of, ability to perform an activity in the manner, or within the range, considered normal for a human being.
- (5) "Health supplement" means any substance, extract or mixture of substances as determined by SAHPRA, sold in dosage forms used or purported for use in restoring, correcting or modifying any physical or mental state by-
  - (a) complementing health.



## Special Requirements and Conditions of Contract HP09-2026SD

- (b) supplementing the diet; or
  - (c) a nutritional effect, and excludes injectable preparations, medicines or substances listed as Schedule 1 or higher in the Medicines Act.
- (6) “Historically Disadvantaged Individual (HDI)” means a South African citizen –
- (i) who, due to the apartheid policy that had been in place, had no franchise in national elections prior to the introduction of the Constitution of the Republic of South Africa, 1983 (Act No 110 of 1983) or the Constitution of the Republic of South Africa, 1993 (Act No 200 of 1993) (“the Interim Constitution”); and / or
  - (ii) who is a female; and / or
  - (iii) who has a disability:
- Provided that a person who obtained South African citizenship on or after the coming to effect of the Interim Constitution, is deemed not to be an HDI.
- (7) “IVD” (in vitro diagnostic) means a medical device, whether used alone or in combination, intended by the manufacturer for the in vitro examination of specimens derived from the human body solely or principally to provide information for diagnostic, monitoring or compatibility purposes.
- (8) “Joint Venture (Incorporated)” means a distinct legal entity formed through the joint ownership of two or more parties, established for contractual collaboration and registered with the Companies and Intellectual Property Commission (CIPC).
- (9) “Joint venture (Unincorporated)” means a project- or bid-specific contractual collaboration between two or more entities, established without creating a separate legal entity.
- (10) "Label", when used as a verb, means brand, mark or otherwise designate or describe, and when used as a noun, means any brand or mark or any written, pictorial, or other descriptive matter appearing on or attached to or packed with and referring to any article or the package containing any article.



## Special Requirements and Conditions of Contract HP09-2026SD

- (11) "Locally produced product" refers to a product whose formulation and conversion processes, including the use of materials and components to manufacture medicines, occur within the Republic of South Africa. This includes active pharmaceutical ingredients (APIs) (imported or locally produced) and excipients to produce finished products. Locally produced product includes **the fill and finish of sterile products** (including vaccines) but **excludes the fill, finish, and packaging of products such as solids, liquids, sterile drops and semi-solid dosage forms.**
- (12) "Management" in relation to an enterprise or business, means an activity inclusive of control and performed daily, by any person who is a principal executive officer of the company, by whatever name that person may be designated, and whether or not that person is a director.
- (13) "manufacture" means all operations including purchasing of material, processing, production, packaging, quality control, release and storage of medicinal products and related control.
- (14) "medical device" means any instrument, apparatus, implement, machine, appliance, implant, reagent for in vitro use, software, material or other similar or related article, including Group III and IV Hazardous Substances contemplated in the Hazardous Substances Act, 1973 (Act No. 15 of 1973)—
- (a) intended by the manufacturer to be used, alone or in combination, for humans or animals, for one or more of the following:
- (i) diagnosis, prevention, monitoring, treatment or alleviation of disease;
  - (ii) diagnosis, monitoring, treatment, alleviation of or compensation for an injury;
  - (iv) investigation, replacement, modification or support of the anatomy or of a physiological process;
  - (iv) supporting or sustaining life;
  - (v) control of conception;
  - (vi) disinfection of medical devices; or
  - (vii) providing information for medical or diagnostic purposes by means of in vitro examination of specimens derived from the human body; and



## Special Requirements and Conditions of Contract HP09-2026SD

(b) which does not achieve its primary intended action by pharmacological, immunological or metabolic means, in or on the human or animal body, but which may be assisted in its intended function by such means;

All medical devices are categorized based on the risk associated with the intended use of the medical device or IVD. Medical devices, including in-vitro diagnostic (IVD) medical devices and non-IVD medical devices, are grouped into four classes including Class A devices presenting the lowest potential risk (e.g. a tongue depressor) and Class D devices presenting the greatest potential risk (e.g. pacemakers) to patients, users and public health.

	<b>RISK</b>	<b>NON-IVD EXAMPLES</b>	<b>IVD EXAMPLES</b>	<b>PHASE II REQUIREMENTS</b>
Class A	Low individual risk & minimal or no public health risk	Surgical retractors/ tongue depressors	Reagents, instruments, specimen receptacle. Microbiological culture medium	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs
Class B	Low-moderate	Hypodermic needle/ suction equipment	Pregnancy self-test kit, urine self-test strips to detect glucose, biochemistry test for gases, hormones, vitamins	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs
Class C	Moderate-high	Lung ventilators	Malaria rapid test, human genetic testing, STD test, Prenatal screening test, Tumour markers, self-monitoring blood glucose	A valid licence to manufacture, or import, distribute or wholesale medical devices or IVDs



## Special Requirements and Conditions of Contract HP09-2026SD

	<b>RISK</b>	<b>NON-IVD EXAMPLES</b>	<b>IVD EXAMPLES</b>	<b>PHASE II REQUIREMENTS</b>
Class D	High	Heart valves /Implantable defibrillator	Screening for HIV/Hepatitis B, detection of Rhesus markers; testing red blood cell antigen or antibodies within ABO blood group system	A valid licence to manufacture, or import, distribute or wholesale medical devises or IVDs

- (15) “medical device or IVD establishment” means a facility used by a manufacturer, wholesaler, distributor, retailer, service provider or an importer of medical devices or IVDs for conducting business;
- (16) “medicine” means:
- (a) any substance or mixture of substances used or purporting to be suitable for use or manufactured or sold for use in
    - (i) the diagnosis, treatment, mitigation, modification or prevention of disease, abnormal physical or mental state or the symptoms thereof in humans; or
    - (ii) restoring, correcting or modifying any somatic or psychic or organic function in humans; and
  - (b) includes any veterinary medicine.
- (17) "Medicines Act" means the Medicines and Related Substances Control Act, 1965 (Act No. 101 of 1965).
- (18) "Minimum order quantity" means the fewest number of units a supplier is willing to sell to a single Participating Authority/Authorities in a single consignment.
- (19) "Package" means anything in or by which any medicine, complementary, veterinary medicines or scheduled substance is enclosed, covered, contained, or packed.
- (20) “Partnership” means a profit-driven arrangement between two or more persons, governed by the Partnership Act, 1939, and South African common law, in which the partners share liability and do not constitute a separate legal entity.

Special Requirements and Conditions of Contract HP09-2026SD

---

- (21) "Person" includes reference to a juristic person.
- (22) "Rand value" means the total estimated value of a contract in Rand denomination which is calculated at the time of tender invitations and includes all applicable taxes and excise duties.
- (23) "Single Exit Price" (SEP) is defined in the Regulations Relating to a Transparent Pricing System for Medicines and Scheduled Substances, under the Medicines and Related Substances Act No 101 of 1965. It is the price set by the manufacturer or importer, including the logistics fee and VAT, and is calculated by multiplying the price of the lowest unit of the medicine or substance by the number of units in the pack.
- (24) "Tender" means a written offer or bid in a prescribed or stipulated form in response to an invitation by an organ of state for the provision of services or goods.
- (25) "Third party manufacturer" refers to any external company or organisation, other than the holder of the Medicines Registration Certificate (MRC), that is responsible for manufacturing the product as indicated on the MRC for the item being offered in the bid. Where such a manufacturer is involved, the bidder must have formal legal agreement in place with the third party and must submit a signed Authorisation Declaration (PBD1.2) from the third party involved.
- (26) "Working days" for the purpose of this document working days refer to Monday to Friday only excluding public holidays.





## SECTION A

### 3. BID DOCUMENT CHECK LIST

All bid documents listed below must be **compiled, indexed, and submitted** in the **exact sequence** specified.

Each document listed must be supported by the relevant annexure, if applicable.

All bid documents **must be duly signed** by a person **authorised to legally bind the bidder**.

**Non-compliance** with any of these requirements **may render a bid non-responsive**, resulting in **disqualification from further evaluation** in accordance with applicable procurement regulations.

The table below serves as a guide to the documents that should be included in the bid submission. While some documents are strongly recommended, they are not considered during the bid evaluation process, however, are required for administrative purposes. Adhering to the suggested compilation sequence is highly recommended.

The absence of mandatory documents will impact the bid's responsiveness. Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
1	CL	Covering Letter Note: Status relating to TAX, License to Manufacture, Certificates etc.	Administrative				
2	BFI	Bid/File Index.	Administrative				



## Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
3	PBD3 & Resolution	Bid Signature Authority; Resolution/Authority to sign bid.	Mandatory				
4	SBD1	SBD 1: Invitation to bid.	Mandatory				
5	PBD4.1	PBD 4.1: Contact Details of Bidder.	Administrative				
6	Consortium	<ul style="list-style-type: none"> <li>• Certified copy of relevant agreement between entities (SRCC Section 4.3)</li> <li>• And any other document as specified in Section 4.3</li> </ul>	Mandatory, if applicable				
7	JV (UNINCORPORATED)	<ul style="list-style-type: none"> <li>• Certified copy of relevant agreement between entities (SRCC Section 4.3)</li> <li>• And any other document as specified in Section 4.3</li> </ul>	Mandatory, if applicable				
8	JV (INCORPORATED)	<ul style="list-style-type: none"> <li>• Certified copy of CIPC registration certificate</li> <li>• Certified copy of relevant agreement (SRCC Section 4.3)</li> <li>• And any other document as specified in Section 4.3</li> </ul>	Mandatory, if applicable				
9	PARTNERSHIP	<ul style="list-style-type: none"> <li>• Certified copy of relevant agreement between entities (SRCC Section 4.3)</li> <li>• And any other document as specified in Section 4.3</li> </ul>	Mandatory, if applicable				
10	CSD	CSD Registration report	Mandatory				
11	TCP	SARS Tax Clearance Pin	Mandatory				
12	CIPC	CIPC/CIPRO company registration certificate	Mandatory				
13	NC	Proof of company ceding mergers, acquisition, and name changes	Administrative				



## Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
14	PBD9.1	PBD9.1: Entity Directors Categorisation and entity ownership profile	Mandatory				
15	ID	Certified copies of Directors/Owners Identification listed in PBD9-2025	Mandatory				
16	SBD4	SBD 4: Declaration of interest	Mandatory				
17	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.	Mandatory				
18	SBD6	SBD 6(1) Indicate Preference Points Claimed in table and space provided.	Mandatory				
19	OWNERSHIP	Company Ownership Organogram	Mandatory, if claiming preferential points				
20	SHARES	Certified Share Register and Share Certificate(s) of HDI member/s	Mandatory, if claiming preferential points				
21	TRUST DEED	Trust /Scheme Deed listing HDI Trustees Beneficiaries and with stipulated benefit. <b>Certified copy required</b>	Mandatory, if applicable and preferential points claimed				
22	HDI ID	ID's of HDI with equity ownership (had no franchise in national elections before the 1983 and 1993 Constitutions). <b>Certified copies required</b>	Mandatory, if claiming preferential points				
23	ID-DISABILITY	ID of HDI disability claimed in SBD 6.1 <b>Certified copies required</b>	Mandatory, if claiming preferential points				
24	DR-NOTE	Medical Certificate detailing the nature and extent of the disability as claimed in SBD 6.1. <b>Certified copies required</b>	Mandatory, if applicable and preferential points claimed				



## Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
25	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.	Mandatory				
26	GMP-LM	SAHPRA approved GMP certificate as alternative to PBD5 (Local manufacturers)	Mandatory				
27	SBD5	SBD5: The National Industrial Participation Programme.	Mandatory				
28	LICMI	Valid licence to manufacture or import (in the name of the bidder), <u>including all annexures</u> . <b>Certified copies required.</b>	Mandatory				
29	LICM	Valid licence to manufacture or import, <u>including all annexures for local manufacturing sites</u> as listed on the MRC of the bidder (applicant). <b>Certified copies required.</b>	Mandatory				
30	LICCM	Valid licence to manufacture/import distribute/wholesale a <b><u>Complementary Medicines</u></b> (in the name of the bidder), <u>including all annexures and DA02 product list</u> : <b>Certified copies required</b>	Mandatory				
31	LICMD	Valid licence to manufacture/import distribute/wholesale a <b><u>medical device or an in vitro diagnostic (IVD)</u></b> (in the name of the bidder), <u>including all annexures</u> : <b>Certified copies required</b>	Mandatory				



## Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
32	MRC	Valid Medicine Registration Certificates (MRC). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.	Mandatory				
33	MRC Annexures	MRC Annexures must be submitted only for newly registered products. Note: The conditions of registration must align with the MRC of the newly registered medicine and must be clearly marked.	Administrative				
34	VARSUM	A valid Variation Summary for any changes on the MRC where applicable as prescribed by SAHPRA GUIDELINE: BAU VARIATIONS COMMUNICATION, latest version - <b>Certified copies</b>	Administrative				
35	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.	Administrative				
36	PBD1.1	PBD 1.1: List of products offered sourced from third party.	Administrative				
37	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party OR alternatively a formal letter from the third party could be included.	Administrative				
38	PI	The original Package Insert (PI), QR code with professional information approved by the MCC or SAHPRA must be submitted for each product offered. Each PI must be clearly marked with the relevant item	Administrative				



## Special Requirements and Conditions of Contract HP09-2026SD

NO	ADMIN CODE	DOCUMENT NAME	MANDATORY DOCUMENT	N/A	YES	NO	REMARK
		number and arranged in numerical order.					
39	PS	Proof of sample submission.	Administrative				
40	BL	Bidder's item list (list of products offered).	Administrative				
41	PRICE	<b>Signed</b> Excel Bid Response i.e. Pricing Schedule. <u>Note: If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.</u>	Mandatory				
42	USB	<b>Set 2 &amp; 3</b> - Universal Serial Bus (USB) Flash Drive / Storage Device with digital copy of the completed bid. <b>Note: Each compilation sequence (document) must be saved as a separate file, with index admin code abbreviations used in each file name.</b>	Administrative				

All bid documents listed above must be sorted, filed, and submitted in the exact order as indicated above

Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.

**The bid document check list is available as Annexure A in an excel spreadsheet format and should be completed by all bidders and submitted in hard copy and as part of the electronic copies of "Set 3: Electronic version of bid documents"**

The NDoH reserves the right to request any non-mandatory bid document or information for clarification, if it does not change the substance of the bid. The bidder will have seven (7) working days to submit the requested document or information.

Digital copies must be identical to hard copy submissions. In the event of a discrepancy, the hard copy takes precedence over the digital copy.



### 3.1.1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all resulting contracts shall be governed by the applicable provisions of the following legislation:

- The Medicine and Related Substances Act, 1965 (Act 101 of 1965).
- The Pharmacy Act, 1974 (Act 53 of 1974).
- The Patents Act, 1978 (Act 57 of 1978), where applicable to intellectual property rights in procurement.
- The Trademarks Act, 1993 (Act 194 of 1993), where relevant to product identification and branding.
- The General Conditions of Contract (GCC), issued in accordance with Treasury Regulation 16A under the Public Finance Management Act, 1999 (Act 1 of 1999).

The Special Requirements and Conditions of Contract (SRCC) shall supplement the GCC. In the event of any conflict between the SRCC and the GCC, the SRCC shall take precedence, except where such conflict contravenes applicable laws, regulations, or Treasury directives.

### 3.1.2. BID INFORMATION SESSION

A non-compulsory online briefing session will be held via an MS Teams Webinar on 20<sup>th</sup> June 2025 at 10H00. Bidders who wish to participate are required to register on MS Teams Webinar no later than Thursday, close of business, 19<sup>th</sup> June 2025, by using the following link.

<https://events.teams.microsoft.com/event/eff5eeda-cd16-4fc0-ab12-777d84dd69aa@a517371c-f316-484c-ac5c-98b76127790a>

Upon successful registration you will receive a confirmation email of your attendance.



## Special Requirements and Conditions of Contract HP09-2026SD

If you experience any challenges with the registration process, please notify the Department via [tenders@health.gov.za](mailto:tenders@health.gov.za) before 19<sup>th</sup> of June 2025.

It is strongly **recommended** that all prospective bidders submit all enquiries related to the advertised tender to [tenders@health.gov.za](mailto:tenders@health.gov.za) . Prospective bidders must submit all enquiries on time to allow the response to reach the bidders before the tender closes.

### 3.1.3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

PHASE I	PHASE II	PHASE III	PHASE IV
<b>Administrative evaluation</b>	<b>Product technical evaluation: Legal and regulatory</b>	<b>Price and Preference Points evaluation</b>	<b>Recommendation and Award</b>
Bidders will be assessed for compliance with the mandatory administrative requirements	Bidders will be evaluated for compliance with the technical mandatory requirements and the product will be evaluated for compliance to the specification.	Bidders will be evaluated w.r.t compliance to HDI and RDP Goals (Price and Preference Points) as per section 6 of this SRCC	Recommendation and award

### 4. PHASE I: ADMINISTRATIVE EVALUATION

Bidders are required to submit all applicable documents relevant to the bidding enterprise or in the event of a consortium, joint venture (incorporated or unincorporated), or partnership, as specified in section 4.3, by the closing date and time of the bid.

All bid documents that require signatures must be duly signed by the individual identified in PBD3 using preferably permanent black ink. Failure to comply with these requirements will result in the bid being declared administratively non-responsive.

The PBD3 must be accompanied by a certified resolution from the board / members/ partners, confirming the authority to sign. The absence of the supporting resolution will render the bid non-responsive, regardless of the PBD3 being signed.





All copies of original documents, as requested in this bid, must be certified, and dated by the Commissioner of Oaths. (No copies of certified copies will be accepted).

#### 4.1. BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the price, mandatory response fields, the excel bid response documents i.e. pricing schedule and Categorization of Directors Profile.

##### **PBD9.1: Director's Categorization and entity ownership profile**

The form attached as PBD9.1 in excel format, forms an integral part of the bid document. Bidders must ensure that it is completed without changing the structure thereof. All columns must be completed in full, and all pages signed. **Attach certified copies of Director/s identification documents (IDs).**

##### **Excel Bid Response i.e., Pricing schedule:**

Bidders are required to submit fully completed and responsive bids by accurately completing all mandatory fields in the Excel Bid Response Document, including pricing information. All prices must be quoted to two (2) decimal places.

Quoted prices must be all-inclusive (including VAT) and reflect the total cost for supply and delivery to the specified destination. The bid price for each product will be deemed applicable to the pack size and unit of measure as specified in the item description.

Bidders are strongly advised to consult the "Definition of Fields" document included in the Bid Response Document for detailed guidance on completing each field correctly. Incomplete or inaccurate submissions, particularly the omission of mandatory fields, may result in the bid being deemed non-responsive and disqualified.

**Delivered Bid Prices offered.**

Final prices submitted must **not exceed** the most recent Single Exit Price (SEP) as recorded on the National Department of Health (NDoH) SEP database.

If the prices submitted at the date and time of bid closure exceed the ex-manufacturer component of the SEP, inclusive of VAT, price negotiations will be required, where applicable, in accordance with the relevant regulations.

If, following negotiations, the bidder offers a price below or equal to the Single Exit Price, the award may be considered. However, the bidder will only qualify for contractual price adjustments up to the most recent Single Exit Price as recorded in the National Department of Health (NDoH) SEP Database.

**4.2. CONSORTIUMS, JOINT VENTURE (INCORPORATED OR UNINCORPORATED), AND PARTNERSHIPS**

If the bidder is not the applicant as required in section 5.2, but any of the following conditions apply, a signed agreement between the bidder and the applicant must be included in the bid submission. This applies in the following cases:

- The bidder is not the applicant on the MRC, but both the bidder and the applicant are subsidiaries of a single legal entity (same parent company).
- The bidder is not the applicant on the MRC, but either the bidder or the applicant is fully or partially owned by the other.



## Special Requirements and Conditions of Contract HP09-2026SD

- The bidder is not the applicant on the MRC, but the bidder and the applicant are part of a technology transfer arrangement.

In such cases, the following documentation **must** be included with the bid:

- A certified copy of the signed agreement between the bidder and the applicant, outlining the terms of their relationship.
- PBD 3 must be completed, and the appointed representative must be authorised to act on behalf of the consortium, joint venture (incorporated or unincorporated), or partnership.

Additionally, all parties involved in the consortium, joint venture (incorporated or unincorporated) or partnership **must** submit the relevant legislative and mandatory documentation as required for this bid, as specified in the SRCC (Special Requirements and Conditions of Contract).

**Each entity (participant)** in the consortium joint venture (incorporated or unincorporated), or partnership **must** submit all mandatory documents including the following:

- Tax Compliance Status (TCS) PIN.
- Proof of Central Supplier Database (CSD) registration (CSD report).

While additional documents issued by the Companies and Intellectual Property Commission (**CIPC**) may be submitted, the inclusion of these two specific forms is mandatory.

- Registration certificate (Form CoR 14.3)
- Notice of change of Directors (Form CoR 39)

The following documents are mandatory for all parties involved in consortium, joint venture (incorporated or unincorporated), or partnership.:

- A valid license to manufacture (bidder and applicant), along with certified copies as per section 5.1, must be provided for all parties involved in the bid.



## Special Requirements and Conditions of Contract HP09-2026SD

- An **MRC** (Medicines Registration Certificate) as per section 5.2, where **one of the parties** in the consortium, joint venture (incorporated or unincorporated) or partnership is identified as the applicant.

The bid must be submitted independently and without collusion or prior consultation with competitors. While communication within a consortium, joint venture (incorporated or unincorporated) or partnership is allowed, sharing bid details with external competitors constitutes **collusive bidding**, which is prohibited.

### 4.3. TAX COMPLIANCE STATUS

Bidders must be registered on the Government's Central Supplier Database (CSD) and include their full CSD report with their bid submission. The NDoH will verify the bidder's tax compliance status through the CSD.

The CSD and the Tax Compliance Status (TCS) PIN are the approved methods for verifying a bidder's tax compliance. Bidders must submit a valid TCS PIN with their bid. It is a condition of this bid that the bidder's tax matters are in order, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

If the bidder is found to be non-compliant with tax obligations during any stage of the evaluation process, the bidder will be notified of their non-compliance status. The bidder will be requested to submit, within seven (7) working days:

- a) Proof of tax compliance
- b) Proof must be provided that arrangements have been made with SARS to address any tax compliance issues, ensuring that the bid adjudication process is not delayed.

By submitting this bid, the bidder confirms that SARS may disclose the bidder's tax compliance status at any time during the contract period. Such confirmation is deemed granted by the bidder upon submission of the bid.



## Special Requirements and Conditions of Contract HP09-2026SD

In the case of a consortium, joint venture (incorporated or unincorporated) or partnership, each party must be registered on the CSD, and their tax compliance status will be verified through the CSD, as described in section 4.3.

Bidders are responsible for ensuring that their CSD information is updated in accordance with the bid documents submitted.

Foreign suppliers, who do not have South African tax obligations or a history of doing business in South Africa, must complete the questionnaire on the SBD1 form. If a foreign bidder is recommended for award, the NDoH will submit the completed SBD1 to SARS at the email address: [GovernmentInstitute@sars.gov.za](mailto:GovernmentInstitute@sars.gov.za). SARS will then issue a confirmation letter to the NDoH, confirming whether the foreign entity has any tax obligations in South Africa.

## 5. PHASE II: PRODUCT TECHNICAL EVALUATION: LEGAL AND REGULATORY

### 5.1. LEGISLATIVE REQUIREMENTS RELATING TO THIS BID

#### 5.1.1 LICENSING REQUIREMENTS

##### **The bidder offering a medicine:**

- Must be the holder of a valid license to manufacture or import medicines, issued in terms of section 22C(1)(b) of the Medicines Act. The bidder must submit a certified copy of the original license, including all annexures.
- Additionally, if the bidder is offering a product manufactured locally, they must submit a certified copy of the original valid license to manufacture medicines, including all annexures, for all local manufacturing sites listed on the MRC.



**The bidder offering a Class A, B, C, or Class D medical device or an in vitro diagnostic (IVD):**

- Must be the holder of a valid license to manufacture, import, distribute, or wholesale medical devices or IVDs, issued in terms of section 22C(1)(b) of the Medicines Act, including all annexures. The bidder must submit a certified copy of the original license, including all annexures relevant to the products offered.
- An information leaflet for the unregistered medical device should be supplied, if required by SAHPRA.

**The bidder offering Category D Complementary medicines:**

- Must be the holder of a valid license to manufacture, import, or export Complementary medicines (Category D), issued in terms of section 22C(1)(b) of the Medicines Act, including the DA02 Product List as issued by SAHPRA. The bidder must submit a certified copy of the original valid license, including all annexures relevant to the products offered.
- An information leaflet for the complementary medicines should be supplied, if required by SAHPRA.

**In the case of a consortium, joint venture (incorporated or unincorporated), and/or partnership.:**

- All involved parties must be holders of the license to manufacture or import medicines, issued in terms of section 22C(1)(b) of the Medicines Act. Companies must submit certified copies of the respective licenses, as described in section 4.3.

If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths.



### **5.1.2 MEDICINE REGISTRATION CERTIFICATE (MRC) REQUIREMENTS AND VARIATION SUMMARIES**

**Items offered must be registered in terms of Section 15 of the Medicines Act and must comply with the conditions of registration for the duration of the contract.**

- In the case of medicines, a certified copy of the original MRC, issued in terms of Section 15(3)(a) of the Medicines Act, must be included with the bid for each item offered.
- Where there is a variation in the MRC, the bidder should submit the Variation Summary.
- The bidder must be indicated as the applicant on each MRC.
- In the event that the bidder is not the applicant, refer to Section 4.3 regarding consortium, joint venture (incorporated or unincorporated), or partnership.
- In the event a product offered is not eligible for registration in terms of Section 15(3)(a) of the Medicines Act, refer to section 5.1.1 relating to Medical Devices, and Complementary medicine requirements.

### **5.1.3 SUBMISSION OF MRC ANNEXURES (CONDITIONS OF REGISTRATION)**

Medicine registration may be subject to conditions as determined by SAHPRA in terms of Section 15(6)(a) of the Medicines Act. These conditions, as outlined in the MRC annexures (conditions of registration), should be submitted in the following instances:

- All newly registered medicines.
- Medicines for which a bid is being placed for the first time.
- In the event of a medicine review or renewal in terms of Section 15(6)(a) of the Medicines Act.

All bidders should submit, where applicable, a valid variation summary as prescribed by the latest version of the SAHPRA GUIDELINE: BAU VARIATIONS COMMUNICATION, along with a certified copy of the original MRC issued by the MCC/SAHPRA.



#### 5.1.4 AUTHORISATION DECLARATION (PBD1.2)

Only the holder of a valid MRC issued in terms of the Medicines Act may submit a bid.

If the holder of the Medicines Registration Certificate (MRC) is not the manufacturer of the product offered in this bid, a third-party manufacturer authorisation is required. In such cases, the bidder must establish a formal legal agreement with the third-party manufacturer and submit a signed Authorisation Declaration (PBD1.2) from the relevant manufacturer as approved by SAPHRA which must be listed on the MRC.

The NDoH reserves the right to verify any information supplied by the bidder in the Authorisation Declaration. Should any information be found to be false or incorrect, the NDoH may exercise any remedies available to it as outlined in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, along with the required annexures, in accordance with these provisions, may result in the invalidation of the bid for the goods or services offered.

No agreement between the bidder and any third party will be binding on the NDoH.

#### 5.1.5 SAMPLES TO BE SUBMITTED TO SAMPLE EVALUATION SITES

**All bidders are required to submit samples, including those who are currently supplying the NDoH with products, to confirm the following:**

- Compliance with the specifications set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines Act.

Failure to submit samples to both institutions listed below will result in the invalidation of the bid for the items offered. Samples must be submitted to each of the depots at the addresses indicated below prior to the closing date and time of the bid:





## Special Requirements and Conditions of Contract HP09-2026SD

GAUTENG MEDICAL SUPPLIES DEPOT	CAPE MEDICAL DEPOT
Ms Pretty Nyokong Contract Manager Tel: 011 628 9001/11 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001

- No samples are to be sent to the NDoH.
- Samples should be clearly marked with the bid number, item number, and the bidder's name and address.
- All samples must be a true representation of the product that will be supplied.
- Bidders must submit at least one original pack of each offered item for evaluation.
- A mock sample may be accepted for a registered product with SAHPRA that is not yet available on the market. The mock sample must be a true representation of the product to be supplied, should a contract be awarded, and must include the product (tablet, capsule, liquid, etc.) in a form that may not be in the original container, along with the SAHPRA-approved artwork and package insert.
- It is the bidder's responsibility to ensure that samples have been received at the addresses provided above.
- All samples for awarded items will be retained for the duration of the contract.
- For **Schedule 6** medicines only, the primary packaging/artwork and package insert, or professional information must be submitted (do not include the product itself).
- Proof of sample submission, including a signed copy of the item list as received by the sample evaluation site, should be submitted with the bid documents by the closing date and time of the bid.
- All samples submitted should include an eligible package insert, QR code or professional information leaflet (as indicated in section 5.1.1) approved by SAHPRA.



- Both institutions will evaluate the samples submitted to ensure compliance with the specifications.

#### 5.1.6 COMPLIANCE WITH SPECIFICATIONS

- Items must comply with the specification as detailed in the bid document.
- The Department reserves the right to award a product with a Specification Deviation.
- The 28-day dispensing pack size is currently being phased out. In the case of medicines for chronic conditions, pack sizes suitable for a 30-day treatment cycle are required.

Where a 30-day dispensing pack size is advertised, and a 28-day dispensing provided, no conversion factor will be utilised. Evaluation will directly compare the 30-day dispensing pack size with other options offered and will not be considered as a specification deviation. All bidders are encouraged to participate in this tender.

### 6. PHASE III: PRICE AND PREFERENCE POINTS EVALUATION

#### 6.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS CLAIMED IN TERMS OF THE REVISED PREFERENTIAL PROCUREMENT REGULATIONS (PPPFA), 2022

Preference points will be evaluated and allocated in accordance with the revised Preferential Procurement Regulations of 2022, issued under sections 2 and 5 of the Act, which aim to promote:

- a) **Empowerment of Historically Disadvantaged Individuals (HDI)**, which refers to South African citizens who:
  - Were denied the right to vote in national elections prior to the introduction of the Constitution of the Republic of South Africa, 1983 (Act No. 110 of 1983) or the Constitution of the Republic of South Africa, 1993 (Act No. 200 of 1993) (referred to as "the Interim Constitution").



## Special Requirements and Conditions of Contract HP09-2026SD

- Are female.
- Have a disability.

b) **Promotion of specific Reconstruction and Development Programme (RDP) goals**, as outlined in section 2(1)(d) of the Act. These goals may include contracting with individuals or categories of individuals historically disadvantaged by unfair discrimination based on race, gender, and disability, and the implementation of programmes from the Reconstruction and Development Programme, as published in Government Gazette No. 16085, dated 23 November 1994.

- **Selected Goal:** The promotion of South African-owned enterprises, specifically ownership held by South African citizens in the bidding enterprise.

### 6.1.1. HDI AND RDP GOAL POINTS CLAIMABLE FOR THIS TENDER

- **HDI Promotion and points claimable:**

NO	DESCRIPTION	CLAIMABLE POINTS
1	Who had no franchise in national elections before the 1983 and 1993 Constitutions	4
2	Who is a female	2
3	Who has a disability	2

- **RDP Goal for this tender and points claimable:**

NO	DESCRIPTION	CLAIMABLE POINTS
1	The promotion of South African owned enterprises	2

### 6.1.2. HDI CLAIMS MADE IN SBD 6.1 MUST BE SUPPORTED BY EVIDENCE BASED DOCUMENTATION

To claim preference points the bidder must complete the SBD6.1 in full and in accordance with the requirements. If the SBD6.1 is not completed in accordance with the requirements no preference points will be allocated.



#### 6.1.2.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS FOR HDI

Percentage (%) of HDI ownership held in the bidding enterprise, should be supported by share certificate and share register i.e. if four (4) points is claimable, then two (2) points will be allocated for 50% ownership.

NO	HDI DESCRIPTION	CLAIMABLE POINTS
1	Who had no franchise in national elections before the 1983 and 1993 Constitutions	4

Equity Ownership claims must be supported by substantiating evidence to be considered for points claimed in SBD6.1.

- **HDI Equity Ownership**

The following supporting documents are mandatory to substantiate claims made for HDI equity ownership:

- Certified copies of identification documents (IDs), and
- Certified copies of Share certificates, and
- Share statement/Share Register reflecting the total number of shares issued by the bidding enterprise and the shares held by each qualifying HDI.

- **HDI Equity Ownership through Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for HDI ownership within a Trust/ Employment Scheme or Similar:

- Certified copy of applicable Trust Deed, and
- Share certificate confirming ownership held by Trust in bidding enterprise, and
- Trust Deed indicating HDIs listed as Trustees and Beneficiaries, and
- Certified copies of identification documents (IDs) of qualifying Trustees and Beneficiaries.



## Special Requirements and Conditions of Contract HP09-2026SD

NO	DESCRIPTION	CLAIMABLE POINTS
2	Who is a female	2

- **Female Ownership**

The following supporting documents are mandatory to substantiate claims made for female ownership:

- Certified copies of IDs, and
- Certified copies of Share certificate/s, and
- Share statement / Share Register reflecting the total number of shares issued by the bidding enterprise and indicating the shares held by South African female/s, and

- **Female Equity Ownership through Trusts / Employment Scheme or Similar**

Should female ownership be held through a Trust Deed / Employment Scheme, such female/s must be listed as trustee and a beneficiary of such Trust Deed/ Employment Scheme and also be actively involved in the management of the Trust Deed/ Employment Scheme.

- Certified copies of IDs

NO	DESCRIPTION	CLAIMABLE POINTS
3	Who has a disability	2

- **Individuals with Disability**

The following supporting documents are mandatory to substantiate claims made for ownership, by individuals with a disability:

- Certified copies of identification documents (IDs), and
- Medical Certificate detailing the nature and extent of the disability required, and
- Certified copies of the share certificate(s) held by HDI member/s with a disability.



- **Equity Ownership for individual with a disability in Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for HDI equity ownership held by individuals with disabilities, who are also trustees or beneficiaries:

- Trust Deed indicating listed HDI owner as trustees and beneficiaries, and
- Certified copies of identification documents (IDs), and
- Medical Certificate detailing the nature and extent of the disability required, and
- Certified copies of the share certificate(s) held by HDI member/s with a disability.

### 6.1.3. RDP GOAL: PROMOTION OF SOUTH AFRICAN OWNED ENTERPRISES

#### 6.1.3.1. CRITERIA USED FOR THE ALLOCATION OF PREFERENTIAL POINTS

Percentage (%) of ownership held by South Africans in the bidding enterprise, supported by share certificate and share register, will be used to calculate claimable points i.e. one (1) point allocated for 50% ownership.

#### 6.1.4. POINTS CLAIMABLE

NO	DESCRIPTION	CLAIMABLE POINTS
4	The promotion of South African owned enterprises	2

- **RDP Goal**

The following supporting documents are mandatory to substantiate claims made for ownership by South African individuals:

- Certified copies of IDs, and
- Certified copies of Share certificate/s, and
- Share statement/Share Register reflecting the total number of shares issued by the bidding enterprise and indicating shares held by South Africans, and



- **RDP Ownership in Trusts / Employment Scheme or Similar**

The following supporting documents are mandatory to substantiate claims made for ownership in Trusts / Employment Scheme or Similar:

- Share certificate(s) reflecting ownership of the Trust / Ownership Scheme in the bidding enterprise.
- Trust Deed indicating those South Africans who are both Trustees and Beneficiaries and who are actively involved in the management of the Trust; and
- Certified copies of IDs the Trustees and Beneficiaries.

## 6.2. **HDI CLAIMS IN CONSORTIUMS, UNINCORPORATED JOINT VENTURES AND PARTNERSHIPS**

Entities forming part of a bidding enterprise, such as those within a consortium, unincorporated joint venture or partnership may claim preferential points for qualifying Historically Disadvantaged Individuals (HDIs).

To validate such claims, a certified copy of the signed agreement between the participating entities must be submitted with the bid. **This agreement must clearly outline:**

- The terms of the relationship,
- The percentage (%) stake of each entity in the bidding enterprise for the purpose of executing the tender.

The claim for preferential points must be aligned to the equity ownership held by qualifying HDI individuals within each participating entity of the bidding enterprise.

Where the partnership is constituted, for example, by two entities with a 60% and 40% stake towards the execution of a tender:

- the qualifying HDI individuals within the 60% partner, will contribute towards 60% of the preferential points that may be earned for the bidding enterprise.



## Special Requirements and Conditions of Contract HP09-2026SD

- Likewise, the HDI individuals within the 40% partner may contribute towards the remaining 40% that may be earned for the bidding enterprise

Each participating entity may therefore only claim HDI points in direct proportion to its stake in the consortium, unincorporated joint venture or partnership, as confirmed in the formal agreement between the entities forming the bidding enterprise

Preferential points are allocated based on the extent of HDI equity ownership held and alignment with applicable Reconstruction and Development Programme (RDP) Goals.

### 6.2.1. FORMULAE - PREFERENCE POINT SYSTEM TO BE APPLIED IN THIS TENDER

#### 6.2.2. FORMULA FOR PRICE (90)

The 90/10 preference point system will be applied in this tender to allocate points for price. This system is applied for acquisition of goods or services with a Rand value **above R50 000 000 (all applicable taxes included)**. The points for price shall be allocated in the following manner:

Responsive bids will be adjudicated by the NDoH on the 90/10-preference point system in terms of which points for price will be awarded to bidders based on:

- The bid price (maximum 90 points)

The following formula will be used to calculate the points for price:

$$Ps = 90 \left( 1 - \frac{Pt - Pmin}{Pmin} \right)$$

Where

Ps = Points scored for price of tender under consideration

Pt = Price of tender under consideration

Pmin = Price of lowest acceptable tender





### 6.2.3. FORMULA FOR HDI PREFERENCE POINTS (10)

$$NEP = \frac{NOP \times EP}{100}$$

Where

NEP = Points awarded for equity ownership by an HDI

NOP = The maximum number of points awarded for equity ownership by an HDI

EP = The percentage of equity ownership of and HDI within the enterprise of business, determined in accordance with the Act and specific provisions contained in the revised Preferential Procurement Regulations, 2022.

## 7. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The NDoH reserves the right to consider locally produced products offered by bidders. Bidders must indicate the manufacturing location of the products in the Excel Bid Response Document.

To provide preference to locally produced products, the definition of a "locally produced product" is limited to the formulation and conversion processes that use materials and components to manufacture medicines (including raw materials, whether imported or locally produced, for active pharmaceutical ingredients (API) and excipients to produce finished products) within the Republic of South Africa. A locally produced product includes the **fill and finish of sterile products** (vaccines small and large volume parenterals. However, it **excludes** the **fill, finish, and packaging of non-sterile dosage forms** such as solids, liquids, sterile drops, and semi-solid formulations.



## Special Requirements and Conditions of Contract HP09-2026SD

Providing that awarding locally produced products does not compromise security of supply or affordability, the quantities allocated for award as locally produced products, may be allocated proportionally, aligning with the percentage of the product volume that will be locally produced.

Preference will be given to bidders of locally produced products if:

- A certified copy of the valid License to Manufacture, as per section 22C(1)(b) of the Medicines Act, for the local manufacturing site (including all applicable annexures) for medicines, complementary medicines, and medical devices/IVDs is submitted.
- The local manufacturing site is listed on the MRC issued by SAHPRA, indicating that the manufacturer is located in the Republic of South Africa.
- The Single Exit Price (SEP) published on the SEP database is not exceeded.
- The local manufacturer has demonstrated the capacity to supply the required volumes based on the data provided in the Excel Bid Response Document.
- The bidder complies with all other clauses contained in this SRCC.

If the necessary documentation or evidence is not included in the bid documents, the bid will not qualify for preference as a locally produced product.

### 8. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

### 9. SUBMISSION OF BIDS

All bid documents must be **compiled, indexed, and submitted** in the **exact sequence** specified. Each document must include the relevant annexure, as indicated in the bid document checklist (**Annexure A**) attached to the bid pack.



## Special Requirements and Conditions of Contract HP09-2026SD

- Submission of bid documents is required unless a specific document is not applicable, in which case the bidder must explicitly indicate "N/A" and provide a justification for its exclusion. If a section is blacked out in the "N/A" field, it is not considered a valid selection option for the bidder.
- All bid documents must be signed in the spaces provided within the document, preferably in permanent black ink.
- All bid documents must be initialled at the bottom of each page in the space provided with "Bidder's Signature...", preferably in permanent black ink.
- Where certified copies of original documents are submitted, bidders must ensure that the certification is original, signed, and dated by the Commissioner of Oaths.
- If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths.
- All SBD bid documents must fully signed and witnessed, where required, preferably in permanent black ink. All mandatory documents as specified in **Annexure A** must be valid at the time of bid closure. The NDoH will not accept updated mandatory bid documents after the bid closure date, unless the document was valid at the time of bid closure but is set to expire during the bid validity period. In such cases, an updated document may only be submitted if specifically requested by the Department.
- Bidders who do not comply with any of the mandatory requirements will be deemed non-responsive and may not be considered for evaluation.

### 10. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time in a sealed package.



## Special Requirements and Conditions of Contract HP09-2026SD

The full name and address of the bidder, including the return address, the bid number, and the closing date, must be clearly indicated on the package.

The bid must comprise of:

- **Set 1** The original **Hard copy bid**, (signed legal documents, including all certificates and documents requested); bound with tabs indicating section as per Annexure A Checklist.
- **Set 2 (Electronic Copies)**, consisting of a scanned PDF of the Hard Copy bid, and saved together with Set 3 on a USB Flash Drive / Storage Device.
- **Set 3 (Excel Spreadsheets)** comprising of the electronically completed Excel spreadsheets.

All fields must be completed. Where the requested information / documentation is not applicable, indicate 'N/A' and provide a comment explaining the reason for non-applicability.

### **Set 1: Hard copy legally binding bid documents.**

Bidders must complete all SBD, PBD and Bid Response forms in permanent black ink, or typed. Where no electronic entry field is provided, bidders must complete the forms in permanent black ink, handwritten. All bid documents must be signed in ink in the spaces provided within the document. All bid documents must be initialed at the bottom of each page.

The following must be applied:

- Where certified copies of original documents are submitted, bidders must ensure that the certification is original and dated by the Commissioner of Oaths.
- If SAHPRA issues an electronic certificate or license, a hard copy must still be provided. This printed version must be certified by a Commissioner of Oaths. Where applicable, all bid documents must be witnessed preferably in permanent black ink.



## Special Requirements and Conditions of Contract HP09-2026SD

---

- The signed hard copy of the bid document will serve as the legal bid document.
- Bidders must submit their complete bid in hard copy format (paper document).
- All pages in the complete bid document must be signed and initiated with preferably permanent black ink.
- The use of correction fluid is not acceptable.
- Any change/s must be clearly indicated and initiated.

### **Note Set 2 & 3**

Bidders must submit a USB flash drive/storage device with a digital copy of the completed bid. Bidders must follow the same compilation sequence as per the index and use the index admin code abbreviation used in the file name.

### **Set 2: PDF of Hard Copy signed legal documents. (i.e., PDF of Set 1)**

Bidders must submit a PDF version of the entire signed hard copy bid, including all certificates and documents requested.

### **Set 3: Electronic version of bid documents**

In addition, bidders must submit the electronic versions, Bid Response Document, and other relevant spreadsheets in Excel (not PDF). All three sets of information must be submitted for the bid to be evaluated. Ensure that the bid price is offered for the product as specified.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.

**11. LATE BIDS**

Bids received after the closing date and time at the address indicated in the bid documents will not be accepted for consideration and, where practical, will be returned unopened to the bidder.

**12. COUNTER CONDITIONS**

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

**13. FRONTING**

The NDoH supports the spirit of the RDP Goals and HDI empowerment and recognizes that true empowerment can only be achieved through individuals and businesses acting in accordance with the Constitution, and in an honest, fair, equitable, transparent, and legally compliant manner. In this regard, the NDoH condemns any form of fronting.

The NDoH encourages bidders to act with honesty during their bid preparation process. Should any fronting, bid rigging, or collusion practices be suspected, the NDoH reserves the right to conduct investigations to verify the accuracy of the representations made in bid documents. Any form of misrepresentation, corruption, or fraudulent practice identified on the part of the bidder may result in serious consequences as specified in the relevant regulations. These consequences may include prohibiting the offending bidder from conducting business with the public sector for a period not exceeding 10 years.

**14. SUPPLIER DUE DILIGENCE**

The NDoH reserves the right to conduct supplier due diligence prior to the final award. This may involve such steps as the Department, in its sole and absolute discretion, deems necessary to satisfy itself regarding, inter alia, the legal, compliance, financial, and operational status and condition of the bidder, supplier, and/or its affiliates (as the case may be).

This may include site visits to assess whether:

- The item is manufactured at the site specified in the bid documentation;
- The bidder has the capacity to meet their allocated or agreed demand.

**15. COMMUNICATION**

The NDoH reserves the right to communicate with bidders post bid closure and during the bid validity period, for the purpose of seeking clarification on documents submitted or extending the validity period of the bid, if necessary. All communication between the bidder and the NDoH must be conducted in writing. Any communication between a bidder and any government official or a person acting in an advisory capacity to the NDoH regarding this bid, during the bid validity period, is strongly discouraged.

Any communication between the NDoH and the bidder, after bid closure may not provide any such bidder with a competitive advantage.

Information obtained during clarification may be shared with relevant committees involved in the tender process, in accordance with applicable procurement protocols and competition regulations.



## Special Requirements and Conditions of Contract HP09-2026SD

---

### 16. CONTACT DETAILS

**Postal address**

Directorate: Affordable Medicines

Private Bag X828

**PRETORIA**

0001

**Physical address**

Directorate: Affordable Medicines

Dr AB Xuma Building

1112 Voortrekker Road,

Block A Pretoria

Townlands 351-JR

**PRETORIA**

0187

Please use the following e-mail address for any queries relating to the bidding process:

- [tenders@health.gov.za](mailto:tenders@health.gov.za)





## SECTION B

### 17. CONTRACT PERIOD

The contract shall be for the period of three years starting 1 May 2026 to 30 April 2029.

### 18. PARTICIPATING AUTHORITIES

Participating Authorities on this contract are: Provincial Departments of Health and other entities as approved by the Accounting Officer:

- Department of Correctional Services;
- South African Military Health Services;

#### Provincial Departments of Health:

- |                 |                |
|-----------------|----------------|
| • Eastern Cape  | • Western Cape |
| • Northern Cape | • Free State   |
| • KwaZulu-Natal | • Limpopo      |
| • Mpumalanga    | • North West   |
| • Gauteng       |                |

Other entities may request to participate in the contract during the contract period. Such requests will only be considered if the awarded suppliers agree and confirm in writing that the inclusion of additional participants will not compromise the security of supply. Participation by other entities is subject to the approval of the Chief Accounting Officer of the NDoH. Appropriate consultation and communication with the contracted suppliers will take place prior to any approval being granted.

**19. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES**

The contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after the award of the contract.

Failure to meet this requirement will result in the inability to process payment for goods.

**20. AWARD CONDITIONS**

NDoH reserves the right to:

- Award the same item as a multiple award to various suppliers (two or more) to address high volume requirements, security of supply and product availability.
- Negotiate prices and minimum order quantities and volumes.
- Award an item with a specification deviation.
- Refrain from applying conversion factors when a 30-day dispensing pack size is advertised, and a 28-day dispensing pack size is offered.
- Combine the quantities and award only one item number, where applicable if an item is advertised as a single item but is included in a therapeutic class and is recommended for award within that class.
- Only award one item in a procurement class will be awarded but could be awarded as a split award.

In cases where the tender does not achieve the most economically advantageous price, the NDoH reserves the right not to award that item.



### 20.1. SPLIT AND MULTIPLE AWARDS

The NDoH reserves the right to issue split or multiple awards, where necessary, to facilitate security of supply. The following will be taken into consideration when contemplating a split or multiple award:

- Source of API and manufacturing site;
- Capacity to meet expected demand as per published estimates in the Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.
- The Minimum Order Quantity (MOQ) for split or multiple awards will be negotiated and aligned to the smallest acceptable value.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

CATEGORY	DIFFERENCE BETWEEN POINTS SCORED	RECOMMENDED PERCENTAGE SPLIT
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10



## Special Requirements and Conditions of Contract HP09-2026SD

Where a split of **three (3) or more** bidders is contemplated, the total score of each will be applied in the following formula to determine the percentage (%) split for each bidder:

For example, the percentage split for the highest scoring bidder will be calculated as follows:

$$\% \text{ Split} = T1/(T1+T2+T3)$$

Where :

- T1 = Score of highest Scoring Bidder
- T2 = Score of second Highest Scoring Bidder
- T3 = Score of third Highest Scoring Bidder

### 20.2. THERAPEUTIC CLASS AWARDS

The *Policy for Classifying Medicines into Therapeutic Classes for Purposes of Therapeutic Interchange* (as published: [https://www.health.gov.za/wp-content/uploads/2021/08/Therapeutic-Interchange-Policy\\_July2021\\_final.pdf](https://www.health.gov.za/wp-content/uploads/2021/08/Therapeutic-Interchange-Policy_July2021_final.pdf); July 2021 ) defines a therapeutic class as a group of medicines that contain active ingredients with comparable therapeutic effects. Medicines within a therapeutic class may not necessarily belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may have different mechanisms of action, adverse reactions, toxicity, and drug interaction profiles. In most cases, however, these medicines exhibit similar efficacy and safety profiles when administered in equipotent doses for a specific indication.



## Special Requirements and Conditions of Contract HP09-2026SD

The ministerially appointed National Essential Medicines List Committee (NEMLC) is responsible for formulating and revising the Standard Treatment Guidelines (STGs) and the Essential Medicines List (EML). Therapeutic classes are specified in the "Medicine Treatment" section of the national STGs, which lists a class of medicines followed by examples, such as HMG-CoA reductase inhibitors (Statins) – e.g., simvastatin. These therapeutic classes are designated when no member of the class offers a significant benefit over another for a specific indication. The NEMLC may designate therapeutic classes for a condition, where applicable.

Such therapeutic classes may be utilised during the contracting process to achieve the most economically advantageous contracts, maximize market volume, and increase competition, thereby offering potential cost efficiencies through robust competition. A single member from the therapeutic class may be awarded on the contract.

HP09-2026SD – Therapeutic Classes			
Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 1	Calcium channel blocker – low dose	Amlodipine 5mg tablet, 28/30 tablets vs Felodipine 5mg tablet, 30 tablets vs Nifedipine 30mg modified release tablet, 28/30 tablets	
Class 2	Calcium channel blocker – standard dose	Amlodipine 10mg tablet, 28/30 tablets vs Felodipine 10mg tablet, 30 tablets vs Nifedipine 60mg modified release tablet, 28/30 tablets	



## Special Requirements and Conditions of Contract HP09-2026SD

## HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 3	ACE-inhibitor - low dose	Benazepril 10mg tablet, 28/30 tablets vs Enalapril 10mg tablet, 28/30 tablets vs Lisinopril 10mg scored tablet, 28/30 tablets vs Perindopril 4mg scored tablet, 28/30 tablets vs Quinapril 20mg scored tablet, 28/30 tablets vs Ramipril 2,5mg scored tablet, 28/30 tablets vs Trandolapril 0,5mg capsule, 30 capsules	
Class 4	ACE-inhibitor - moderate dose	Benazepril 20mg tablet, 30 tablets vs Enalapril 20mg tablet, 28/30 tablets vs Lisinopril 20mg tablet, 28/30 tablets vs Perindopril 8mg tablet, 28/30 tablets vs Quinapril 40mg tablet, 28/30 tablets vs Ramipril 5mg tablet/ capsule, 28/30 tablets/capsules vs Trandolapril 2mg capsule, 30 capsules	



## Special Requirements and Conditions of Contract HP09-2026SD

## HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 5	Bisphosphonate	Alendronic acid 10mg tablet, 28/30 tablets vs Alendronic acid 70mg tablet, 4 tablets vs Risedronic acid 35mg tablet, 4 tablets vs Risedronic acid 5mg tablet, 28/30 tablets vs Risendronic acid 150mg tablet, 1 tablet	
Class 6	Alpha blocker - for BPH	Alfuzosin 10mg tablet, 30 tablets vs Doxazosin 4mg tablet, 30 tablets vs Silodosin 8mg capsule, 30 capsules vs Tamsulosin 0,4mg capsule, 28/30 capsules vs Terazosin 10mg tablet, 28/30 tablets	
Class 7	Alpha blocker - BPH (titration doses)	Doxazosin 1mg tablet; 30 tablets vs Silodosin 4mg capsule; 30 capsules vs Terazosin 1mg tablet; 28/30 tablets	
Class 8	Alpha blocker - for Phaeochromocytoma - low dose	Doxazosin 4mg tablet; 30 tablets vs Terazosin 10mg tablet; 28/30 tablets	
Class 9	Acetylsalicylic acid	Aspirin 100mg tablet, 28 tablets vs Aspirin 300mg scored tablet, 14 tablets vs Aspirin 81mg tablet, 28 tablets	



## Special Requirements and Conditions of Contract HP09-2026SD

## HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 10	Proton pump inhibitor (PPI) – Standard dose (28's)	Lansoprazole 30mg capsule, 28/30 capsules (Series 1) vs Omeprazole 20mg tablet/capsule, 28/30 tablets/capsules (Series 2) vs Pantoprazole 40mg tablet/capsule, 28/30 tablets/capsules (Series 3) vs Rabeprazole 20mg tablet/capsule, 28/30 tablets/capsules (Series 4)	Class 10 will be considered as a series with Class 11 and Class 12
Class 11	Proton pump inhibitor (PPI) - Low dose	Lansoprazole 15mg tablet/capsule, 28/30 tablets/capsules (Series 1) vs Omeprazole 10mg tablet/capsule, 28/30 tablets/capsules (Series 2) vs Pantoprazole 20mg tablet/capsule, 28/30 tablets/capsules (Series 3) vs Rabeprazole 10mg tablet/capsule, 28/30 tablets/capsules (Series 4)	Class 11 will be considered as a series with Class 10 and Class 12
Class 12	Proton pump inhibitor (PPI) – Standard dose (14's)	Lansoprazole 30mg capsule, 14 capsules (Series 1) vs Omeprazole 20mg tablet/capsule, 14 tablets/capsules (Series 2) vs Pantoprazole 40mg tablet/capsule, 14 tablets/capsules (Series 3) vs Rabeprazole 20mg tablet/capsule, 14 tablets/capsules (Series 4)	Class 12 will be considered as a series with Class 10 and Class 11





## Special Requirements and Conditions of Contract HP09-2026SD

## HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 13	Fibrates	Bezafibrate 400mg tablet; 28/30 tablets vs Fenofibrate 200mg capsule; 30 capsules vs Gemfibrozil 600mg tablet; 30 tablets	
Class 14	Cardio-selective b-blocker - high dose	Acebutolol 200mg tablet/capsule, 28/30 tablets/capsules vs Atenolol 100mg tablet, 28/30 tablets vs Bisoprolol 10mg tablet, 28/30 tablets vs Metoprolol 200mg tablet/capsule, 28/30 tablets/capsules	
Class 15	Cardio-selective b-blocker - standard dose	Acebutolol 100mg tablet/capsule, 28/30 tablets/capsules vs Atenolol 50mg tablet, 28/30 tablets vs Bisoprolol 5mg tablet, 28/30 tablets vs Metoprolol 100mg tablet/capsule, 28/30 tablets/capsules	
Class 16	Nitrates, short acting	Glyceryl trinitrate 0,5mg sublingual tablet, 50 tablets vs Isosorbide dinitrate 5mg sublingual tablet, 50 tablets	
Class 17	Angiotensin II receptor blocker - low dose	Candesartan 4mg tablet, 28/30 tablets vs Losartan 50mg tablet, 28/30 tablets vs Valsartan 40mg tablet, 28/30 tablets	



## Special Requirements and Conditions of Contract HP09-2026SD

## HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 18	Angiotensin II receptor blocker - standard dose	Candesartan 32mg tablet, 28/30 tablets vs Losartan 100mg tablet, 28/30 tablets vs Valsartan 160mg tablet, 28/30 tablets	
Class 19	Non-sedating antihistamine	Cetirizine 10mg tablet, 28/30 tablets vs Fexofenadine 120mg tablet, 28/30 tablets	
Class 20	Quetiapine - standard dose	Quetiapine 100mg modified release tablet, 90 tablets vs Quetiapine 100mg tablet, 90 tablets	
Class 21	Quetiapine - intermediate dose	Quetiapine 200mg modified release tablet, 60 tablets vs Quetiapine 200mg tablet, 60 tablets	
Class 22	Quetiapine - higher dose	Quetiapine 300mg modified release tablet, 60 tablets vs Quetiapine 300mg tablet, 60 tablets	
Class 23	PDE5-inhibitors	Sildenafil 20mg tablet; 90 tablets vs Sildenafil 25mg tablets; 4 tablets vs Sildenafil 50mg scored tablets; 4 tablets vs Tadalafil 20mg tablets; 4 tablets vs Vardenafil 5mg tablets; 4 tablets vs Vardenafil 10mg scored tablets; 4 tablets	



## Special Requirements and Conditions of Contract HP09-2026SD

## HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 24	Dopamine agonists for Parkinsons disease	Pramipexole 0,25mg tablet; 100 tablets vs Ropinarole 1mg tablet; 84 tablets	
Class 25	SSRI- low dose	Citalopram 10mg tablet, 28/30 tablets vs Escitalopram 5mg tablets, 30 tablets vs Sertraline 50mg scored tablets, 30 tablets	
Class 26	SSRI-standard dose	Citalopram 20mg tablet, 28/30 tablets vs Escitalopram 10mg tablets, 30 tablets vs Sertraline 100mg scored tablets, 30 tablets	
Class 27	DOACs - Loading dose	Apixaban 5mg tablets; 60 tablets (Series 1) vs Rivaroxaban 20mg tablet; 28/30 tablets (Series 2)	Class 27 will be considered as a series with Class 28
Class 28	DOACs - Prophylaxis	Apixaban 2,5mg tablets; 28/30 tablets (Series 1) vs Rivaroxaban 10mg tablet; 30 tablets (Series 2)	Class 28 will be considered as a series with Class 29
Class 29	HMG CoA reductase inhibitors	Atorvastatin 5mg tablet; 30 tablets vs Pravastatin 20mg tablet; 28 tablets vs Rosuvastatin 2,5mg tablet; 30 tablets vs Simvastatin 10mg tablet; 28/30 tablets	



## Special Requirements and Conditions of Contract HP09-2026SD

## HP09-2026SD – Therapeutic Classes

Therapeutic Class Number	Therapeutic class description	Members of the therapeutic class	Comments
Class 30	HMG CoA reductase inhibitor	Atorvastatin 10mg tablet; 28/30 tablets vs Pravastatin 40mg tablet; 30 tablets vs Rosuvastatin 5mg tablet; 28/30 tablets vs Simvastatin 20mg tablet; 28/30 tablets	
Class 31	HMG CoA reductase inhibitor	Atorvastatin 20mg tablet; 30 tablets vs Pravastatin 80mg tablet; 28/30 tablets vs Rosuvastatin 10mg tablet; 28/30 tablets vs Simvastatin 40mg tablet; 30 tablets	
Class 32	Thiazide Diuretics low dose	Hydrochlorothiazide 12,5mg tablet; 28/30 tablets vs Indapamide 1,5mg tablet; 30 tablets	
Class 33	Thiazide Diuretics standard dose	Hydrochlorothiazide 25mg tablet; 28/30 tablets vs Indapamide 2,5mg tablet; 30 tablets	

**20.3. SERIES AWARDS**

Items will be considered to be awarded in a series where:

Dose titration is required e.g. a single molecule in a class is awarded across all strengths and pack sizes to allow for incremental dosing. Such an approach is required to ensure seamless dose titration, simplify supply and distribution, support healthcare worker use and acceptance, and improve patient adherence.



## Special Requirements and Conditions of Contract HP09-2026SD

**The following items will be awarded in a series:**

Item No	Items Specification
30	Apixaban 2,5mg tablets; 28/30 tablets [Items 30 + 31 will be considered a series]
31	Apixaban 5mg tablets; 60 tablets [Items 30 + 31 will be considered a series]
179	Lansoprazole 15mg tablet/capsule; 28/30 tablets/capsules [Items 179 + 180 + 181 will be considered a series]
180	Lansoprazole 30mg capsule; 14 capsules [Items 179 + 180 + 181 will be considered a series]
181	Lansoprazole 30mg capsule; 28/30 capsules [Items 179 + 180 + 181 will be considered a series]
239	Omeprazole 10mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]
240	Omeprazole 20mg tablet/capsule; 14 tablets/capsules [Items 239 + 240 + 241 will be considered a series]
241	Omeprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]
251	Pantoprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 251 + 252 + 253 will be considered a series]
252	Pantoprazole 40mg tablet/capsule; 14 tablets/capsules [Items 251 + 252 + 253 will be considered a series]
253	Pantoprazole 40mg tablet/capsule; 28/30 tablets/capsules [Items 251 + 252 + 253 will be considered a series]
295	Rabeprazole 10mg tablet/capsule; 28/30 tablets/capsules [Items 295 + 296 + 297 will be considered a series]
296	Rabeprazole 20mg tablet/capsule; 14 tablets/capsules [Items 295 + 296 + 297 will be considered a series]
297	Rabeprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 295 + 296 + 297 will be considered a series]
310	Rivaroxaban 10mg tablet; 30 tablets [Items 310 + 311 + 312 will be considered a series]



## Special Requirements and Conditions of Contract HP09-2026SD

Item No	Items Specification
311	Rivaroxaban 15mg tablet; 42 tablets [Items 310 + 311 +312 will be considered a series]
312	Rivaroxaban 20mg tablet; 28/30 tablets [Items 310 + 311 +312 will be considered a series]

**20.4. PROCUREMENT CLASS**

A procurement class is a grouping of medicines that share the same or similar registered clinical indications. While these medicines may vary in composition, pack size, strength, dosage form, source, mechanism of action, and other pharmacological properties, they have not yet undergone therapeutic interchange review. This classification aims to support the supply chain in adapting to market availability fluctuations to ensure continued access. Only one item within a procurement class will be awarded, though a split award remains a possibility.

Procurement Class	Members of the procurement class
Class 1	Acetylcysteine 200mg tablet; 20/25 tablets Vs Acetylcysteine 600mg tablet; 10 tablets

**20.5. REFERENCE PRICING**

The following items, as specified in the table below, are published with reference price based on clinical review.

Item No	Item Description	Reference Price
209	Methylphenidate 18 - 20mg modified release tablet/capsule; 30 tablets/capsules	R64.15
210	Methylphenidate 27 - 30mg modified release tablet/capsule; 30 tablets/capsules	R96.22



## Special Requirements and Conditions of Contract HP09-2026SD

Item No	Item Description	Reference Price
211	Methylphenidate 36 - 40mg modified release tablet/capsule; 30 tablets/capsules	R128.29

**20.6. NEGOTIATIONS**

The NDoH reserves the right to negotiate prices, minimum order quantities, and supply volumes with bidders prior to the award of the contract. The negotiation process will be conducted at the discretion of the NDoH and in a manner it deems appropriate.

Proposed minimum order quantities (MOQs) should facilitate direct delivery to health establishments.

Where applicable, if an item is advertised as a single item but is included in a therapeutic class and is recommended for award within that class, the Department reserves the right to combine the volumes and award only one item number. In such cases, the Department will negotiate the awarding of combined volumes with the preferred bidder/s.

In addition, the NDoH reserves the right to review prices, minimum order quantities, and supply volumes with successful bidders after the contract award, as part of the contract management process. For more information on price adjustments based on systematic review refer to section 22.

**20.7. NON-COMMITMENT**

The NDoH reserves the right not to award, in part or in full. The Department also reserves the right to withdraw or amend any of the bid conditions, by providing notice in writing to all bidders prior to the closing of the bid or post-award.

If an incorrect award has been made, the NDoH reserves the right to remedy the matter in any manner it deems fit, including the cancellation of the contract.

**21. POST AWARD CONDITIONS**

Regulation 16(A)6.6 of the Treasury Regulations, issued under the Public Finance Management Act, 1999 (Act No. 1 of 1999), allows the Accounting Officer of a department, constitutional institution, or public entity to request participation in any contract arranged through a competitive bidding process by any state organ. This participation requires written approval from both the state organ and the relevant contracted suppliers.

The NDoH may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns, and the availability of items registered in terms of the Medicines Act at the date and time of bid closure. In these circumstances, the NDoH reserves the right to cancel the contract for an item or adjust the quantity awarded based on projected changes in demand. The Department will notify the contracted supplier within a reasonable time of the expected change. However, where patient safety is a concern, these changes may be implemented with immediate effect.

**22. PRICE REVIEW**

The NDoH anticipates three types of price review processes that may be implemented during the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the local and international marketplaces.





## 22.1. ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on the submission of a complete price breakdown per instructions below for all relevant products; and assessment of the rationality of this price breakdown by the NDoH.

## 22.2. INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components.
  - Active Pharmaceutical Ingredient/s (API);
  - Formulation;
  - Packaging;
  - Logistics (this includes transportation, warehousing, and distribution);
  - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The NDoH reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.



## Special Requirements and Conditions of Contract HP09-2026SD

- Items for which price breakdowns were not presented in the prescribed format at the time of bid closure, will render such item(s) ineligible for price adjustments.

### 22.3. PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE. Rates are sourced from the Reserve Bank ([www.resbank.co.za](http://www.resbank.co.za)).

Eligibility for favourable Contractual Price Adjustments may be withdrawn considering evidence of poor compliance with contractual obligations.

**Base average RoE for this tender will be as follows, per currency:**

CURRENCY	BASE AVERAGE RATES OF EXCHANGE AVERAGE FOR THE PERIOD 01 DECEMBER 2024 TO 31 MAY 2025
Rand per US Dollar	<b>R18.45</b>
Rand per Br Pound	<b>R23.64</b>
Rand per Euro	<b>R19.83</b>
Rand per Yuan Renminbi	<b>R2.54</b>
Rand per Indian Rupee	<b>R0.21</b>
Rand per Swiss Franc	<b>R21.05</b>
Rand per Australian Dollar	<b>R11.65</b>
Rand per Danish Krone	<b>R2.65</b>



## Special Requirements and Conditions of Contract HP09-2026SD

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 December 2024 to 31 May 2025 using the South African Reserve Bank published rates for the specific currency.

### 22.4. APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Official applications for price adjustment consideration must be submitted to the NDoH at [cpapharma@health.gov.za](mailto:cpapharma@health.gov.za) before the submission deadlines specified in the tables below.

The application must contain the following information:

- Contract description;
- Date of application;
- CPA cycle applied for;
- Items to be considered for CPA (Item no, NSN and Description).

The application must be submitted on a company letter head, signed, scanned and submitted to the CPA mailbox ([cpapharma@health.gov.za](mailto:cpapharma@health.gov.za)) no later than the submission date as indicated in the table below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price. With reference to paragraph 4.2, the supplier will only be eligible for contractual price adjustments up to the most recent Single Exit Price value as recorded in the National Department of Health (NDoH) SEP Database.



## Special Requirements and Conditions of Contract HP09-2026SD

**22.4.1. EXCEPTIONAL PRICE ADJUSTMENTS BEFORE START OF CONTRACT**

The contracted supplier may apply for an exceptional price adjustment before the start of the contract. These will be activated if the absolute change between the base RoE and the six-month retrospective average RoE indicated in the table below fluctuates by more than 10%. This adjustment applies to eligible components subject to CPA price adjustments based on the bid closure price.

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
0.01	01 October 2025 – 31 March 2026	03 April 2026	01 May 2026

**22.4.2. ROUTINE PRICE ADJUSTMENTS**

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
1	01 May 2026 - 31 October 2026	03 November 2026	01 December 2026
2	01 November 2026 - 30 April 2027	03 May 2027	01 June 2027
3	01 May 2027 - 31 October 2027	03 November 2027	01 December 2027
4	01 November 2027 - 30 April 2028	03 May 2028	01 June 2028
5	01 May 2028 - 31 October 2028	03 November 2028	01 December 2028



## Special Requirements and Conditions of Contract HP09-2026SD

### 22.4.3. EXCEPTIONAL PRICE ADJUSTMENTS DURING CONTRACT PERIOD

Contracted suppliers may request exceptional price adjustments during the contracted period according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three-month retrospective average RoE indicated in the table below fluctuates by more than 10%.

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
0.1	01 May 2026 - 31 July 2026	03 August 2026	01 September 2026
1.1	01 November 2026 - 31 January 2027	03 February 2027	01 March 2027
2.1	01 May 2027 - 31 July 2027	03 August 2027	01 September 2027
3.1	01 November 2027 - 31 January 2028	03 February 2028	01 March 2028
4.1	01 May 2028 - 31 July 2028	03 August 2028	01 September 2028
5.1	01 November 2028 - 31 January 2029	03 February 2029	01 March 2029

Suppliers who received exceptional adjustments will, thereafter, receive routine adjustments based on the average exchange rate over the preceding three months, rather than the standard six-month historical average. The specific periods used to calculate the average rate of exchange (RoE) for these adjustments are outlined in the table below:

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE POST EXCEPTIONAL ADJUSTMENT	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
1	01 August 2026 - 31 October 2026	03 November 2026	01 December 2026
2	01 February 2027- 30 April 2027	03 May 2027	01 June 2027
3	01 August 2027- 31 October 2027	03 November 2027	01 December 2027



## Special Requirements and Conditions of Contract HP09-2026SD

REVIEW	PERIOD FOR CALCULATING ADJUSTMENT AVERAGE ROE POST EXCEPTIONAL ADJUSTMENT	SUBMISSION OF REQUEST FOR PRICE REVIEW TO REACH THE OFFICE BY	DATE FROM WHICH ADJUSTED PRICES WILL BECOME EFFECTIVE
4	01 February 2028- 30 April 2028	03 May 2028	01 June 2028
5	01 August 2028 - 31 October 2028	03 November 2028	01 December 2028

**22.5. PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW**

The NDoH reserves the right to review both local and international market prices to identify the lowest comparable pricing. Should this review reveal prices lower than those stipulated in the contract, the Department may initiate price negotiations with the contracted supplier.

If the outcome of this negotiation is deemed unfavourable, the NDoH reserves the right to terminate the award for the item in question.

**23. QUALITY**

Products and contracted suppliers must conform to the conditions of registration of the product in terms of the Medicines Act for the full duration of this contract. In the event that the product and or contracted supplier does not conform to the conditions of registration of the product, NDOH reserves the right to cancel the contract.

**24. DELIVERY AND QUANTITIES****24.1. DELIVERY BASIS**

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to at all times.



## Special Requirements and Conditions of Contract HP09-2026SD

---

The initial lead time, as proposed in the bid response document, will be calculated from the date of award of the contract and **not** from the date of placement of the first order. This lead time may not exceed 75 calendar days from the date of award from when the contract circular signed by the National Department of health has been published.

Lead time within the contract period is defined as the time from the submission of the order to the supplier to the time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time may result in penalties being enforced, as per sections 21 and 22 of the General Conditions of Contract (GCC).

### **24.2. QUANTITIES**

The quantities reflected in the bid are estimated and no guarantee, either explicit or implied, is given regarding the actual quantity that will be procured during the contract period. Fluctuations in monthly demand may occur.

The NDoH reserves the right to negotiate MOQs where necessary. In cases where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two months' demand for all items, in alignment with the needs of Participating Authority/Authorities.



## SECTION C

### 25. SUPPLIER PERFORMANCE MANAGEMENT

Supplier performance management will be the responsibility of the Participating Authorities, with oversight from the NDoH. If supplier performance disputes cannot be resolved between the contracted supplier and the Participating Authority, the NDoH must be informed for corrective action.

The NDoH, in collaboration with Participating Authorities, will monitor the performance of contracted suppliers throughout the duration of this contract. This will include, but is not limited to, the following areas:

- Ongoing supplier performance monitoring through compliance visits
- Adherence to reporting requirements
- Attendance of quarterly supplier meetings
- Execution of orders and delivery performance
- Management of order cancellations and product substitutions
- Identification and correction of irrational or misaligned orders
- Delivery schedule adherence
- Assurance of continuity of supply

#### 25.1. COMPLIANCE WITH REPORTING REQUIREMENTS:

Suppliers must adhere to the reporting schedule and mechanism established by the NDoH. At a minimum, suppliers must submit the following information in the specified format and mechanism, after receiving training provided by the NDoH:

- All transactional data relating to orders
- A monthly age analysis
- Production pipeline data and forecasts, including:
  - Number of units of the item available (stock on hand)
  - Number of units of the item in Quality Assurance, awaiting release





## Special Requirements and Conditions of Contract HP09-2026SD

- Number of units of the item in the current month's production plan
- Status of outstanding orders

### **25.2 Suppliers will be required to attend compulsory quarterly meetings**

The NDoH will schedule and hold quarterly meetings with contracted suppliers. These meetings will include, but not be limited to, a review of supplier performance and the forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain, benefiting both suppliers and Participating Authorities.

### **25.3 ORDER PLACEMENT AND DELIVERY:**

- Orders will be placed as needed during the contract period, with delivery points specified by the relevant Participating Authority/Authorities.
- The instructions on the official order form regarding supply, dispatch, and submission of invoices must be strictly adhered to.
- Under no circumstances should the contracted supplier deviate from the orders issued by the Participating Authority/Authorities, unless written instruction is received from the relevant participating authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- A Participating Authority is under no obligation to accept any quantity that exceeds the ordered quantity.
- To facilitate the efficient implementation of the direct delivery strategy, contracted suppliers must pack orders according to the purchase order for the relevant health establishment.
- Only orders made using an official, authorized purchase order format are valid.
- Suppliers must acknowledge receipt of all purchase orders received from Participating Authorities in the manner stipulated by the relevant Participating Authority.



#### **25.4 ORDER CANCELLATIONS AND SUBSTITUTION:**

The Participating Authority/Authorities reserve the right to cancel any order if the lead time exceeds 14 days. In such instances, they may, at their discretion, procure supplies of equivalent quality and quantity as a substitute for the goods not delivered in accordance with the contract, in line with Section 21.6 of the General Conditions of Contract.

Should this occur, the Participating Authority may source the item from an alternative supplier, and any cost difference between the contracted supplier's price and the price of the substitute item will be for the account of the contracted supplier.

#### **25.5 IRRATIONAL OR MISALIGNED ORDERS:**

In cases where an order is received that appears to be irrational or misaligned with estimates, the contracted supplier must consult the relevant Participating Authority prior to processing the order.

In the event of short supply, incorrect delivery, or misaligned orders, the supplier must issue a credit note within 15 calendar days of receiving both the credit request and the relevant supporting documentation from the participating authority.

#### **25.6 DELIVERY ADHERENCE**

- Products and related documentation must be delivered in accordance with the terms, conditions, and delivery instructions stipulated in the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the NDoH. The NDoH reserves the right to update these minimum data requirements as needed (Annexure B).
- Invoices must clearly reflect both the "proprietary name" (brand name/trade name), which is unique to a particular medicine and approved under section 15(4) of the Medicines Act, and the item description as it appears in the contract circular and Master Health Product List (MHPL).



## Special Requirements and Conditions of Contract HP09-2026SD

---

- The supplier must ensure that products are delivered in accordance with the appropriate storage conditions, as per the product's conditions of registration. Delivery is deemed complete upon signature of receipt by the delegated official.
- Any discrepancies between the invoice and the physical stock, or damaged stock, must be reported to the contracted supplier within a reasonable time, or as otherwise arranged with the supplier. This time period should allow for verification of the quantities received upon delivery.

Contracted suppliers will be responsible for the collection of goods delivered erroneously or in an incorrect condition, as formally arranged in consultation with the Participating Authorities. The Participating Authorities may recoup any expenses associated with the failure to collect such goods in accordance with the agreement.

### **25.7 CONTINUITY OF SUPPLY**

Contracted suppliers must maintain at least two months' supply of the estimated quantity at the start of the contract and ensure a continuous supply throughout the contract's duration. If order fulfilment for a specific item deviate by 20% from the average monthly estimate for three consecutive months on a rolling basis, suppliers must notify the NDoH/Contract Management Unit (CMU) within two weeks of becoming aware of the discrepancy. In such cases, the supplier should engage with the NDoH and the relevant participating authority to update the demand forecast, align supply volumes accordingly, and prevent supply challenges.

Suppliers are expected to engage regularly with Participating Authorities to review demand and plan proactively to ensure uninterrupted supply.

Special Requirements and Conditions of Contract HP09-2026SD

---

Contracted suppliers must promptly inform all participating authorities and NDoH of any circumstances that may result in an interrupted supply, including but not limited to:

- Regulatory actions that may impact their GMP status or the status of entities on which they rely;
- Anticipated issues with the availability of active pharmaceutical ingredients (API);
- Industrial actions;
- Challenges with the manufacturing pipeline;
- Any other supply-related challenges.

Official communication regarding continuity of supply should be directed to [stockalert@health.gov.za](mailto:stockalert@health.gov.za) , as well as the Participating Authorities.

Official communication regarding payment challenges should be directed to [medacc@health.gov.za](mailto:medacc@health.gov.za) , as well as the relevant Participating Authorities.

All official communications must include details of corrective actions taken by the contracted supplier to ensure continuous supply.

If the contracted supplier is unable to supply the awarded item, the supplier are required to source an alternative product that meets the same specifications.

In the case of a split or multiple awards, the alternative product must not be sourced from another contracted supplier for the same product. The alternative product must be supplied at the current price of the contracted item.

Special Requirements and Conditions of Contract HP09-2026SD

---

Prior to supplying an alternative product including items authorised for procurement utilising Section 21 and Section 26 of the MARSA or 101, the contracted supplier must seek approval from the NDoH and provide a sample to the two health establishments as outlined in section 5.4 of this SRCC. The contracted supplier must also provide the following information to the NDoH:

- Name of the product to be supplied;
- Quantities to be supplied;
- The period for which the product will be supplied. This provision applies only to emergency supply situations and cannot be used for routine or continuous supply.

If a contracted supplier is unable to supply the contracted item for a period **not exceeding six months**, the NDoH reserves the right to reallocate volumes proportionally to an alternative contracted supplier for the duration of the supply interruption.

If a contracted supplier is unable to supply a contracted item for a period **exceeding six months** for any reason, the NDoH reserves the right to cancel the contract, as outlined in Section 23 of the General Conditions of Contract (GCC), Clause 21.2.

Suppliers may be penalized for failing to meet the contractual lead time, as stipulated in Section 22 of the GCC.



## **26. REPORTING**

The NDoH will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements. The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.

## **27. PACKAGING, LABELLING AND BARCODES**

### **27.1. PACKAGING**

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- All medicines must be supplied in complete, patient-ready packaging in the specified pack size, using containers that are properly sealed and labelled in compliance with Medicines Act. Packaging must be in a ready-to-dispense format that does not require any manipulation, packing, or repacking by the dispensing healthcare workers.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where the supplier recommends a particular stacking and storage configuration, this should be clearly illustrated on the outer packaging.



## Special Requirements and Conditions of Contract HP09-2026SD

- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
  - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering.
  - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
- Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
  - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering.
  - The shipper pack must contain only one product, mixing multiple products in a single shipper is not allowed.
  - The outer packaging must be clearly marked as a "Part Box".

### 27.2. LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on both corners (length and breadth) all shipper packs, including any part boxes:
  - Item name as contained in the contract circular and the Master Health Product List (MHPL),
  - Registered product name;
  - Number of units in pack;
  - Batch number;
  - Expiry date;
  - Storage conditions;
  - Barcode.



## Special Requirements and Conditions of Contract HP09-2026SD

- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g., thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly colored background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines Act.

### 27.3. BARCODES

- All unit and shipper packs should be marked with the appropriate barcode.
- The European Article Numbering Code 13 (EAN 13).

### 28. SHELF LIFE

- Unless SAHPRA has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
  - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry and,
  - Applications are approved by the Participating Authorities before execution of orders; and,
  - Upon notification of the remaining expired stock, such products will be collected and disposed of by the supplier at their own cost and,
  - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.





## Special Requirements and Conditions of Contract HP09-2026SD

- If short-dated products are delivered without the undertaking, the following penalty formula will be applied for invoicing of short-dated products:
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept the product with a shelf-life of less than 12 months.

### 29. DISCONTINUATION OF CONTRACTED PRODUCT SUPPLY

It is the responsibility of the contracted supplier to ensure continuous supply of the contracted product until the end date of the contract, as stipulated in the Letter of Acceptance (SDB 7.1).

If the contracted supplier foresees a potential long-term interruption in supply, the supplier must submit a written letter to the Director-General of Health at least six months prior to the anticipated interruption. The letter must include the following:

- The reason for the long-term interruption.
- The impact this will have on the contract.
- The proposed solution or suggested way forward.

The supplier may only interrupt supply to a Participating Authority after informing the Director-General of Health and receiving written approval from the NDoH. It is the responsibility of the National Department of Health to communicate the outcome of this matter to the Participating Authorities.

If the contracted supplier decides to discontinue a contracted product with immediate effect, the Department reserves the right to source the item from an alternative supplier. If the price from the alternative supplier exceeds the contracted price, the supplier discontinuing the product will be liable for the price difference for a period of six months.



### **30. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS**

If a contracted supplier plans to merge with or be acquired by another entity, or intends to cede the contract to another supplier, the contracted supplier must inform the NDoH in writing as soon as they become aware of such an event.

Should the contracted supplier plan to cede a contracted item to another supplier, they must submit an official request in writing to the NDoH at least three months prior to the proposed effective date. The NDoH reserves the right to either accept or decline the request to transfer the contractual obligations to the new supplier under the current terms of the contract, or to cancel the contract altogether.

The contracted supplier is also required to inform the NDoH as soon as they become aware of any changes to their address, name, or contact details. These updates must also be reflected on the Central Supplier Database (CSD).

### **31. CANCELLATION OF CONTRACT**

A request for the cancellation of a contract from a contracted supplier will only be considered if:

- A formal cancellation request in writing addressed to the Director-General: National Department of Health; and
- Evidence in support of the request is submitted.

The contracted supplier is obligated to continue supplying the contracted item under the existing terms and conditions of the contract until the NDoH has formally approved the cancellation request. Once approved, the NDoH will notify the Participating Authorities of the contract cancellation.

### **32. THIRD PARTIES**

Participating Authorities will not make payment to or consult with a third party. No third party is entitled to put an account of a Participating Authority/Authorities on hold.

**END**

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
1	Acebutolol 100mg tablet/capsule; 28/30 tablets/capsules	Class 15	Pack of 28/30 tablets/capsules	14,383,691
2	Acebutolol 200mg tablet/capsule; 28/30 tablets/capsules	Class 14	Pack of 28/30 tablets/capsules	2,091,943
3	Acetazolamide 250mg tablet; 100 tablets		Pack of 100 tablets	107,730
4	Acetazolamide 250mg tablet; 28/30 tablets		Pack of 28/30 tablets	344,668
5	Acetylcysteine 200mg tablet; 20/25 tablets	Procurement class 1	Pack of 20/25 tablets	290,386
6	Acetylcysteine 600mg tablet; 10 tablets	Procurement class 1	Pack of 10 tablets	290,386
7	Acitretin 10mg capsule; 28/30 capsules		Pack of 28/30 capsules	6,316
8	Acitretin 25mg capsule; 28/30 capsules		Pack of 28/30 capsules	14,556
9	Alendronic acid 10mg tablet; 28/30 tablets	Class 5	Pack of 28/30 tablets	62,797
10	Alendronic acid 70mg tablet; 4 tablets	Class 5	Pack of 4 tablets	80,797
11	Alfacalcidol 0,25mcg capsule; 28/30 capsules		Pack of 28/30 capsules	212,080
12	Alfacalcidol 1mcg capsule; 28/30 capsules		Pack of 28/30 capsules	56,548
13	Alfuzosin 10mg tablet; 30 tablets	Class 6	Pack of 30 tablets	5,355,648
14	Allopurinol 100mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,148,600
15	Allopurinol 100mg tablet; 56/60 tablets		Pack of 56/60 tablets	453,579
16	Allopurinol 300mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,981,830
17	Alprazolam 0,5mg tablet; 30 tablets		Pack of 30 tablets	71,831
18	Amiodarone 200mg tablet; 28/30 tablets		Pack of 28/30 tablets	70,934
19	Amisulpiride 200mg tablet; 28/30 tablets		Pack of 28/30 tablets	584,982
20	Amisulpiride 50mg tablet; 28/30 tablets		Pack of 28/30 tablets	184,860
21	Amitriptyline 10mg tablet; 100 tablets		Pack of 100 tablets	43,560
22	Amitriptyline 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	2,848,662

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
23	Amitriptyline 25mg tablet; 100 tablets		Pack of 100 tablets	160,510
24	Amitriptyline 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	9,228,867
25	Amitriptyline 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	578,813
26	Amitriptyline 25mg tablet; 84/90 tablets		Pack of 84/90 tablets	192,266
27	Amlodipine 10mg tablet; 28/30 tablets	Class 2	Pack of 28/30 tablets	46,661,798
28	Amlodipine 5mg tablet; 28/30 tablets	Class 1	Pack of 28/30 tablets	34,994,567
29	Amlodipine 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	6,238,038
30	Apixaban 2,5mg tablets; 28/30 tablets [Items 30 + 31 will be considered a series]	Class 28 In a series with Class 27 Series 2	Pack of 28/30 tablets	293,972
31	Apixaban 5mg tablets; 60 tablets [Items 30 + 31 will be considered a series]	Class 27 in a series with Class 28 Series 2	Pack of 60 tablets	139,930
32	Aripiprazole 10mg tablet; 30 tablets		Pack of 30 tablets	33,406
33	Aripiprazole 15mg tablet; 30 tablets		Pack of 30 tablets	21,540
34	Aripiprazole 5mg tablet; 30 tablets		Pack of 30 tablets	26,512
35	Aspirin 100mg tablet; 28/30 tablets	Class 9	Pack of 28/30 tablets	41,954,347
36	Aspirin 300mg scored tablet; 14 tablets	Class 9	Pack of 14 tablets	42,314,347
37	Aspirin 300mg scored tablet; 96 tablets		Pack of 96 tablets	288,733
38	Aspirin 81mg tablet; 28/30 tablets	Class 9	Pack of 28/30 tablets	41,954,347
39	Atenolol 100mg tablet; 28/30 tablets	Class 14	Pack of 28/30 tablets	2,105,003
40	Atenolol 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	71,820
41	Atenolol 50mg tablet; 28/30 tablets	Class 15	Pack of 28/30 tablets	14,489,771
42	Atorvastatin 5mg tablet; 30 tablets	Class 29	Pack of 30 tablets	34,686,460
43	Atorvastatin 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,788,396
44	Atorvastatin 10mg tablet; 28/30 tablets	Class 30	Pack of 28/30 tablets	17,993,115

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
45	Atorvastatin 20mg tablet; 30 tablets	Class 31	Pack of 30 tablets	2,969,340
46	Atorvastatin 40mg tablet; 30 tablets		Pack of 30 tablets	801,983
47	Baclofen 10mg tablet; 30 tablets		Pack of 30 tablets	1,904,916
48	Baclofen 25mg tablet; 30 tablets		Pack of 30 tablets	270,070
49	Benazepril 10mg tablet; 28/30 tablets	Class 3	Pack of 28/30 tablets	72,849,993
50	Benazepril 20mg tablet; 30 tablets	Class 4	Pack of 30 tablets	13,868,603
51	Betamethasone 0,5mg tablet; 100 tablets		Pack of 100 tablets	5,360
52	Bezafibrate 400mg tablet; 28/30 tablets	Class 13	Pack of 28/30 tablets	268,247
53	Bisoprolol 10mg tablet; 28/30 tablets	Class 14	Pack of 28/30 tablets	2,093,143
54	Bisoprolol 5mg tablet; 28/30 tablets	Class 15	Pack of 28/30 tablets	14,460,491
55	Bromocriptine 2,5mg tablet; 28/30 tablets		Pack of 28/30 tablets	22,241
56	Bupropion 150mg tablet; 30 tablets		Pack of 30 tablets	16,429
57	Bupropion 300mg tablet; 30 tablets		Pack of 30 tablets	12,901
58	Cabergoline 0,5mg tablet; 4 tablets		Pack of 4 tablets	70,610
59	Calcitriol 0,25mcg capsule; 30 capsules		Pack of 30 capsules	15,573
60	Calcium salt providing 168mg - 250mg elemental calcium, chewable tablet; 168 tablets		Pack of 168 tablets	1,748,772
61	Calcium carbonate providing 500mg elemental calcium, soluble tablet; 10 tablets		Pack of 10 tablets	10,660,394
62	Calcium carbonate providing 500mg elemental calcium, soluble tablet; 30 tablets		Pack of 30 tablets	11,878,214
63	Candesartan 32mg tablet; 28/30 tablets	Class 18	Pack of 28/30 tablets	1,023,359
64	Candesartan 4mg tablet; 28/30 tablets	Class 17	Pack of 28/30 tablets	1,737,605
65	Captopril 25mg tablet; 60 tablets, scored		Pack of 60 tablets scored	28,765
66	Carbamazepine 200mg modified release tablet; 30 tablets		Pack of 30 tablets	49,580

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
67	Carbamazepine 200mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,799,781
68	Carbamazepine 200mg tablet; 56/60 tablets		Pack of 56/60 tablets	2,876,938
69	Carbamazepine 200mg tablet; 84/90 tablets		Pack of 84/90 tablets	1,461,001
70	Carbamazepine 400mg modified release tablet; 28/30 tablets		Pack of 28/30 tablets	506,437
71	Carbidopa 25mg and Levodopa 100mg tablet; 100 tablets		Pack of 100 tablets	211,993
72	Carbidopa 25mg and Levodopa 250mg tablet; 100 tablets		Pack of 100 tablets	52,742
73	Carbimazole 5mg tablet; 100 tablets		Pack of 100 tablets	343,527
74	Carbimazole 20mg tablet; 100 tablets		Pack of 100 tablets	18,600
75	Carvedilol 12,5mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	2,579,379
76	Carvedilol 25mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	2,026,174
77	Carvedilol 6,25mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	1,516,859
78	Cetirizine 10mg tablet; 28/30 tablets	Class 19	Pack of 28/30 tablets	8,156,396
79	Cetirizine 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	820,591
80	Chloroquine 200mg tablet/capsule; 100 tablets/capsules		Pack of 100 tablets/capsules	90,662
81	Chloroquine 200mg tablet/capsule; 20 tablets/capsules		Pack of 20 tablets/capsules	148,485
82	Chlorphenamine 4mg tablet; 10 tablets		Pack of 10 tablets	19,548,378
83	Chlorphenamine 4mg tablet; 30 tablets		Pack of 30 tablets	6,645,129
84	Chlorpromazine 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	430,898
85	Chlorpromazine 100mg tablet; 56/60 tablets		Pack of 56/60 tablets	514,860
86	Citalopram 10mg tablet; 28/30 tablets	Class 25	Pack of 28/30 tablets	91,818
87	Citalopram 20mg tablet; 28/30 tablets	Class 26	Pack of 28/30 tablets	2,886,363
88	Clonazepam 0,5mg tablet; 84/90 tablets		Pack of 84/90 tablets	292,119

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
89	Clonazepam 2mg tablet; 84/90 tablets		Pack of 84/90 tablets	155,231
90	Clonidine 0,025mg tablet; 30 tablets		Pack of 30 tablets	22,880
91	Clonidine 0,025mg tablet; 100 tablets		Pack of 100 tablets	29,630
92	Clopidogrel 75mg tablet; 28/30 tablets		Pack of 28/30 tablets	317,201
93	Clozapine 25mg tablet; 100 tablets		Pack of 100 tablets	144,584
94	Clozapine 100mg tablet; 100 tablets		Pack of 100 tablets	283,842
95	Colchicine 0.5mg tablet; 12 tablets		Pack of 12 tablets	643,170
96	Deferasirox 180mg film-coated tablet; 30 tablets		Pack of 30 tablets	4,265
97	Deferasirox 250mg tablet; 28/30 tablets		Pack of 28/30 tablets	3,901
98	Deferasirox 500mg tablet; 28/30 tablets		Pack of 28/30 tablets	6,256
99	Desmopressin 0,1mg tablet; 30 tablets		Pack of 30 tablets	21,386
100	Desmopressin 0,2mg tablet; 30 tablets		Pack of 30 tablets	19,740
101	Desmopressin 120mcg melt tablet; 30 tablets		Pack of 30 tablets	1,478
102	Desmopressin 240mcg melt tablet; 30 tablets		Pack of 30 tablets	710
103	Dexamethasone 0,5mg tablet; 100 tablets		Pack of 100 tablets	19,860
104	Diazepam 5mg tablet; 100 tablets		Pack of 100 tablets	97,815
105	Diazepam 5mg tablet; 14 tablets		Pack of 14 tablets	169,336
106	Diazoxide 25mg capsule; 100 capsules		Pack of 100 capsules	2,632
107	Diclofenac 50mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,880,627
108	Diclofenac 50mg tablet; 9 tablets		Pack of 9 tablets	127,000
109	Digoxin 0,0625mg tablet; 100/120 tablets		Pack of 100/120 tablets	5,260
110	Digoxin 0,25mg tablet; 28/30 tablets		Pack of 28/30 tablets	422,838

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
111	Doxazosin 1mg tablet; 30 tablets	Class 7	Pack of 30 tablets	515,846
112	Doxazosin 4mg tablet; 30 tablets	Class 6	Pack of 30 tablets	5,391,648
113	Doxazosin 4mg tablet; 30 tablets	Class 8	Pack of 30 tablets	1,626,402
114	Enalapril 10mg tablet; 28/30 tablets	Class 3	Pack of 28/30 tablets	73,089,993
115	Enalapril 20mg tablet; 28/30 tablets	Class 4	Pack of 28/30 tablets	13,964,603
116	Enalapril 5mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	11,173,764
117	Ergocalciferol 50 000 IU tablet; 100 tablets		Pack of 100 tablets	98,256
118	Escitalopram 5mg tablet; 30 tablets	Class 25	Pack of 30 tablets	91,638
119	Escitalopram 10mg tablets; 30 tablets	Class 26	Pack of 30 tablets	2,862,363
120	Ezetimibe 10mg tablet; 30 tablets		Pack of 30 tablets	65,440
121	Fenofibrate 200mg capsule; 30 capsules	Class 13	Pack of 30 capsules	215,783
122	Felodipine 10mg tablet; 30 tablets	Class 2	Pack of 30 tablets	46,395,398
123	Felodipine 5mg tablet; 30 tablets	Class 1	Pack of 30 tablets	34,790,567
124	Ferrous salt, providing 50 to 65mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	19,851,724
125	Ferrous salt, providing 50 to 65mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule; 56/60 tablets/capsules		Pack of 56/60 tablets/capsules	2,354,221
126	Ferrous salt, providing 50 to 65mg elemental iron, alone or in combination with other elements/vitamins tablet/capsule; 84/90 tablets/capsules		Pack of 84/90 tablets/capsules	1,715,404
127	Fexofenadine 120mg tablet; 28/30 tablets	Class 19	Pack of 28/30 tablets	8,156,396
128	Fludrocortisone 0,1mg tablet; 100 tablets		Pack of 100 tablets	2,282
129	Fluoxetine 20mg scored tablet; 28/30 tablets		Pack of 28/30 tablets	65,366
130	Fluoxetine 20mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	3,044,719
131	Fluoxetine 20mg tablets/capsules; 100 tablets/capsules		Pack of 100 tablets/capsules	222,187
132	Folic acid 5mg tablet; 100 tablets		Pack of 100 tablets	312,536



ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
133	Folic acid 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	29,849,781
134	Furosemide 40mg tablet; 112/120 tablets		Pack of 112/120 tablets	400,677
135	Furosemide 40mg tablet; 28/30 tablets		Pack of 28/30 tablets	10,737,191
136	Furosemide 40mg tablet; 56/60 tablets		Pack of 56/60 tablets	3,991,851
137	Furosemide 40mg tablet; 84/90 tablets		Pack of 84/90 tablets	880,750
138	Furosemide 500mg tablet; 100 tablets		Pack of 100 tablets	11,872
139	Gabapentin 100mg capsule; 100 capsules		Pack of 100 capsules	52,607
140	Gabapentin 300mg capsule; 100 capsules		Pack of 100 capsules	30,487
141	Gabapentin 400mg capsule; 100 capsules		Pack of 100 capsules	2,897
142	Gemfibrozil 600mg tablet; 30 tablets	Class 13	Pack of 30 tablets	215,747
143	Glibenclamide 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,913,414
144	Glibenclamide 5mg tablet; 56/60 tablets		Pack of 56/60 tablets	913,563
145	Glibenclamide 5mg tablet; 84/90 tablets		Pack of 84/90 tablets	298,558
146	Gliclazide 80mg scored tablet; 60 tablets		Pack of 60 tablets	77,328
147	Glimepiride 1mg tablet; 28/30 tablets		Pack of 28/30 tablets	3,051,847
148	Glimepiride 2mg tablet; 28/30 tablets		Pack of 28/30 tablets	6,516,102
149	Glimepiride 4mg tablet; 28/30 tablets		Pack of 28/30 tablets	5,964,730
150	Glyceryl trinitrate 0,5mg sublingual tablet; 50 tablets	Class 16	Pack of 50 tablets	800,361
151	Haloperidol 1,5mg tablet; 100 tablets		Pack of 100 tablets	328,220
152	Haloperidol 5mg tablet; 100 tablets		Pack of 100 tablets	165,858
153	Haloperidol 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,889,860
154	Haloperidol 5mg tablet; 56/60 tablets		Pack of 56/60 tablets	328,700

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
155	Hydralazine 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	1,520,546
156	Hydralazine 25mg tablet; 84/90 tablets		Pack of 84/90 tablets	458,220
157	Hydrochlorothiazide 12,5mg tablet; 28/30 tablets	Class 32	Pack of 28/30 tablets	91,555,768
158	Hydrochlorothiazide 25mg tablet; 28/30 tablets	Class 33	Pack of 28/30 tablets	29,178,858
159	Hydrocortisone 10mg scored tablet; 100 tablets		Pack of 100 tablets	26,297
160	Hyoscine butylbromide 10mg tablet; 10 tablets		Pack of 10 tablets	7,958,319
161	Ibuprofen 200mg tablet; 15 tablets		Pack of 15 tablets	33,855,762
162	Ibuprofen 200mg tablet; 42 tablets		Pack of 42 tablets	3,691,336
163	Ibuprofen 200mg tablet; 84/90 tablets		Pack of 84/90 tablets	1,301,908
164	Ibuprofen 400mg tablet; 15 tablets		Pack of 15 tablets	10,806,591
165	Ibuprofen 400mg tablet; 84/90 tablets		Pack of 84/90 tablets	1,789,567
166	Indapamide 1,5mg tablet; 30 tablets	Class 32	Pack of 30 tablets	91,528,138
167	Indapamide 2,5mg tablet; 30 tablets	Class 33	Pack of 30 tablets	29,095,158
168	Indomethacin 25mg capsule; 100 capsules		Pack of 100 capsules	1,336,757
169	Isosorbide dinitrate 10mg tablet; 84/90 tablets		Pack of 84/90 tablets	616,217
170	Isosorbide dinitrate 5mg sublingual tablet; 50 tablets	Class 16	Pack of 50 tablets	800,361
171	Isosorbide mononitrate 20mg; 56/60 tablets		Pack of 56/60 tablets	166,975
172	Isotretinoin 10mg capsule; 60 capsules		Pack of 60 capsules	10,673
173	Isotretinoin 20mg capsules; 60 capsules		Pack of 60 capsules	18,388
174	Lamotrigine 100mg tablet; 56/60 tablets		Pack of 56/60 tablets	616,430
175	Lamotrigine 200mg tablet; 56/60 tablets		Pack of 56/60 tablets	86,100
176	Lamotrigine 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	506,706

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
177	Lamotrigine 50mg tablet; 56/60 tablets		Pack of 56/60 tablets	580,913
178	Lamotrigine 5mg dispersible tablet; 60 tablets		Pack of 60 tablets	6,280
179	Lansoprazole 15mg tablet/capsule; 28/30 tablets/capsules [Items 179 + 180 + 181 will be considered a series]	Class 11 Series 1 (In a Series with Class 10 & Class 12)	Pack of 28/30 tablets/capsules	6,551,839
180	Lansoprazole 30mg capsule; 14 capsules [Items 179 + 180 + 181 will be considered a series]	Class 12 Series 1 (In a Series with Class 10 & Class 11)	Pack of 14 capsules	8,954,312
181	Lansoprazole 30mg capsule; 28/30 capsules [Items 179 + 180 + 181 will be considered a series]	Class 10 Series 1 (In a Series with Class 11 & Class 12)	Pack of 28/30 capsules	9,307,294
182	Leflunomide 10mg tablet; 30 tablets		Pack of 30 tablets	7,076
183	Leflunomide 20mg tablet; 30 tablets		Pack of 30 tablets	90,405
184	Levetiracetam 250mg tablets; 30 tablets		Pack of 30 tablets	248,683
185	Levetiracetam 500mg tablets; 30 tablets		Pack of 30 tablets	220,410
186	Levetiracetam 750mg tablets; 30 tablets		Pack of 30 tablets	138,424
187	Levothyroxine sodium 0,025mg tablet; 28/30 tablets		Pack of 28/30 tablets	98,972
188	Levothyroxine sodium 0,05mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,377,123
189	Levothyroxine sodium 0,1mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,436,059
190	Lisinopril 10mg scored tablet; 28/30 tablets	Class 3	Pack of 28/30 tablets	72,849,993
191	Lisinopril 20mg tablet; 28/30 tablets	Class 4	Pack of 28/30 tablets	13,868,603
192	Lithium 250mg tablet; 100 tablets		Pack of 100 tablets	141,938
193	Lithium 400mg tablet; 100 tablets		Pack of 100 tablets	30,620
194	Loperamide 2mg tablet; 6 tablets		Pack of 6 tablets	8,245,225
195	Lorazepam 1mg tablet; 100 tablets		Pack of 100 tablets	127,001
196	Lorazepam 2,5mg tablet; 100 tablets		Pack of 100 tablets	34,449
197	Losartan 100mg tablet; 28/30 tablets	Class 18	Pack of 28/30 tablets	1,066,559
198	Losartan 50mg tablet; 28/30 tablets	Class 17	Pack of 28/30 tablets	1,816,805

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
199	Mesalazine 400mg tablet; 90 tablets		Pack of 90 tablets	33,633
200	Metformin 500mg tablet; 112/120 tablets		Pack of 112/120 tablets	1,010,500
201	Metformin 500mg tablet; 56/60 tablets		Pack of 56/60 tablets	16,521,439
202	Metformin 500mg tablet; 84/90 tablets		Pack of 84/90 tablets	4,996,135
203	Metformin 850mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,222,614
204	Metformin 850mg tablet; 56/60 tablets		Pack of 56/60 tablets	10,347,954
205	Metformin 850mg tablet; 84/90 tablets		Pack of 84/90 tablets	4,910,579
206	Methyldopa 250mg tablet; 56/60 tablets		Pack of 56/60 tablets	1,174,054
207	Methyldopa 250mg tablet; 84/90 tablets		Pack of 84/90 tablets	1,051,497
208	Methylphenidate 10mg tablet; 30 tablets		Pack of 30 tablets	1,652,873
209	Methylphenidate 18 - 20mg modified release tablet/capsule; 30 tablets/capsules		Pack of 30 tablets/capsules	230,000
210	Methylphenidate 27 - 30mg modified release tablet/capsule; 30 tablets/capsules		Pack of 30 tablets/capsules	106,888
211	Methylphenidate 36 - 40mg modified release tablet/capsule; 30 tablets/capsules		Pack of 30 tablets/capsules	23,279
212	Metoclopramide 10mg tablet; 10 tablets		Pack of 10 tablets	5,747,273
213	Metoclopramide 10mg tablet; 100 tablets		Pack of 100 tablets	72,100
214	Metoprolol 100mg tablet/capsule; 28/30 tablets/capsules	Class 15	Pack of 28/30 tablets/capsules	14,383,691
215	Metoprolol 200mg tablet/capsule; 28/30 tablets/capsules	Class 14	Pack of 28/30 tablets/capsules	2,091,943
216	Midazolam 15mg tablet; 20 tablets		Pack of 20 tablets	2,120
217	Midazolam 7,5mg tablet; 20 tablets		Pack of 20 tablets	1,854
218	Minoxidil 10mg tablet; 100 tablets		Pack of 100 tablets	4,996
219	Minoxidil 5mg tablet; 100 tablets		Pack of 100 tablets	5,610
220	Montelukast 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	70,622

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
221	Montelukast 4mg chewable tablet; 28/30 tablets		Pack of 28/30 tablets	8,036
222	Montelukast 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	60,400
223	Morphine 10mg modified release tablet; 60 tablets		Pack of 60 tablets	44,703
224	Morphine 30mg modified release tablet; 60 tablets		Pack of 60 tablets	40,000
225	Morphine 60mg modified release tablet; 60 tablets		Pack of 60 tablets	2,060
226	Nicotinamide 100mg tablet; 28/30 tablets		Pack of 28/30 tablets	352,958
227	Nicotinamide 100mg tablet; 84/90 tablets		Pack of 84/90 tablets	14,220
228	Nifedipine 10mg capsule; 100 capsules		Pack of 100 capsules	24,232
229	Nifedipine 30mg modified release tablet; 28/30 tablets	Class 1	Pack of 28/30 tablets	34,844,567
230	Nifedipine 5mg capsule; 100 capsules		Pack of 100 capsules	74,318
231	Nifedipine 60mg modified release tablet; 28/30 tablets	Class 2	Pack of 28/30 tablets	46,395,398
232	Nimodipine 30mg tablet; 100 tablets		Pack of 100 tablets	4,486
233	Olanzapine 2,5mg tablet; 28/30 tablets		Pack of 28/30 tablets	145,644
234	Olanzapine 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	596,254
235	Olanzapine 5mg Oral Dispersible Tablet; 28/30 tablets		Pack of 28/30 tablets	21,606
236	Olanzapine 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	840,182
237	Olanzapine 10mg Oral Dispersible Tablet; 28/30 tablets		Pack of 28/30 tablets	43,965
238	Omeprazole 10mg dispersible tablet; 28/30 tablets		Pack of 28/30 tablets	378,210
239	Omeprazole 10mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]	Class 11 Series 1 (In a Series with Class 10 & Class 12)	Pack of 28/30 tablets/capsules	6,551,839
240	Omeprazole 20mg tablet/capsule; 14 tablets/capsules [Items 239 + 240 + 241 will be considered a series]	Class 12 Series 1 (In a Series with Class 10 & Class 11)	Pack of 14 tablets/capsules	8,954,312
241	Omeprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 239 + 240 + 241 will be considered a series]	Class 10 Series 1 (In a Series with Class 11 & Class 12)	Pack of 28/30 tablets/capsules	9,307,294
242	Orphenadrine 50mg tablet; 28/30 tablets		Pack of 28/30 tablets	4,377,904

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
243	Orphenadrine 50mg tablet; 56/60 tablets		Pack of 56/60 tablets	1,897,848
244	Orphenadrine 50mg tablet; 84/90 tablets		Pack of 84/90 tablets	382,532
245	Oxazepam 10mg tablet; 100 tablets		Pack of 100 tablets	52,568
246	Oxazepam 15mg tablet; 100 tablets		Pack of 100 tablets	9,256
247	Oxazepam 30mg tablet; 100 tablets		Pack of 100 tablets	24,426
248	Oxybutynin 5mg tablet; 84/90 tablets		Pack of 84/90 tablets	347,883
249	Pancreatin 150mg equivalent to Amylase 8000 FIP units, Lipase 10000 FIP units and Protease 600 FIP units per capsule; 100 capsules		Pack of 100 capsules	27,429
250	Pancreatin 300mg equivalent to Amylase 18 000 FIP units, Lipase 25000 FIP units and Protease 1000 FIP units per capsule; 100 capsules		Pack of 100 capsules	36,004
251	Pantoprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 251 + 252 + 253 will be considered a series]	Class 11 Series 1 (In a Series with Class 10 & Class 12)	Pack of 28/30 tablets/capsules	6,551,839
252	Pantoprazole 40mg tablet/capsule; 14 tablets/capsules [Items 251 + 252 + 253 will be considered a series]	Class 12 Series 1 (In a Series with Class 10 & Class 11)	Pack of 14 tablets/capsules	8,954,312
253	Pantoprazole 40mg tablet/capsule; 28/30 tablets/capsules [Items 251 + 252 + 253 will be considered a series]	Class 10 Series 1 (In a Series with Class 11 & Class 12)	Pack of 28/30 tablets/capsules	9,307,294
254	Paracetamol 500mg tablet; 100 tablets		Pack of 100 tablets	11,974,876
255	Paracetamol 500mg tablet; 20 tablets		Pack of 20 tablets	126,742,213
256	Perindopril 4mg scored tablet; 28/30 tablets	Class 3	Pack of 28/30 tablets	72,957,993
257	Perindopril 8mg tablet; 28/30 tablets	Class 4	Pack of 28/30 tablets	13,904,603
258	Phenobarbitone 30mg tablet; 28/30 tablets		Pack of 28/30 tablets	449,505
259	Phenobarbitone 30mg tablet; 56/60 tablets		Pack of 56/60 tablets	177,086
260	Phenobarbitone 30mg tablet; 84/90 tablets		Pack of 84/90 tablets	145,996
261	Phenytoin 100mg capsule/tablet; 100 tablets/capsules		Pack of 100 tablets/capsules	280,675
262	Phenytoin 100mg capsule/tablet; 84/90 tablets/capsules		Pack of 84/90 tablets/capsules	1,657,481
263	Potassium chloride 600mg tablet; 100 tablets		Pack of 100 tablets	394,586
264	Pramipexole 0,25mg tablet; 100 tablets	Class 24	Pack of 100 tablets	21,475

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
265	Pravastatin 20mg tablet; 28 tablets	Class 29	Pack of 28 tablets	34,686,520
266	Pravastatin 40mg tablet; 30 tablets	Class 30	Pack of 30 tablets	17,846,315
267	Pravastatin 80mg tablet; 28/30 tablets	Class 31	Pack of 28/30 tablets	2,791,540
268	Prednisone 5mg tablet; 100 tablets		Pack of 100 tablets	571,948
269	Prednisone 5mg tablet; 28/30 tablets		Pack of 28/30 tablets	10,799,500
270	Prednisone 5mg tablet; 56/60 tablets		Pack of 56/60 tablets	1,505,388
271	Pregabalin 150mg capsule; 56/60 capsules		Pack of 56/60 capsules	57,602
272	Pregabalin 25mg capsule; 56/60 capsules		Pack of 56/60 capsules	81,376
273	Pregabalin 75mg capsule; 56/60 capsules		Pack of 56/60 capsules	179,585
274	Probenecid 500mg tablet; 100 tablets		Pack of 100 tablets	216
275	Promethazine 10mg tablet; 100 tablets		Pack of 100 tablets	388
276	Promethazine 25mg tablet; 100 tablets		Pack of 100 tablets	597,463
277	Propranolol 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	349,038
278	Propranolol 10mg tablet; 50 tablets		Pack of 50 tablets	175,666
279	Propranolol 10mg tablet; 84/90 tablets		Pack of 84/90 tablets	162,656
280	Propranolol 40mg tablet; 56/60 tablets		Pack of 56/60 tablets	108,348
281	Propranolol 40mg tablet; 84/90 tablets		Pack of 84/90 tablets	36,054
282	Pyridostigmine 10mg tablet; 50 tablets		Pack of 50 tablets	48,599
283	Pyridostigmine 60mg tablet; 150 tablets		Pack of 150 tablets	33,394
284	Pyridoxine (Vitamin B6) 25mg tablet; 100 tablets		Pack of 100 tablets	363,090
285	Pyridoxine (Vitamin B6) 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	28,964,502
286	Quetiapine 100mg modified release tablet; 90 tablets	Class 20	Pack of 90 tablets	161,434

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
287	Quetiapine 100mg tablet; 90 tablets	Class 20	Pack of 90 tablets	161,434
288	Quetiapine 200mg modified release tablet; 60 tablets	Class 21	Pack of 60 tablets	170,208
289	Quetiapine 200mg tablet; 60 tablets	Class 21	Pack of 60 tablets	170,208
290	Quetiapine 25mg tablet; 100 tablets		Pack of 100 tablets	155,933
291	Quetiapine 300mg modified release tablet; 60 tablets	Class 22	Pack of 60 tablets	48,084
292	Quetiapine 300mg tablet; 60 tablets	Class 22	Pack of 60 tablets	48,084
293	Quinapril 20mg scored tablet; 28/30 tablets	Class 3	Pack of 28/30 tablets	72,849,993
294	Quinapril 40mg tablet; 28/30 tablets	Class 4	Pack of 28/30 tablets	13,868,603
295	Rabeprazole 10mg tablet/capsule; 28/30 tablets/capsules [Items 295 + 296 + 297 will be considered a series]	Class 11 Series 1 (In a Series with Class 10 & Class 12)	Pack of 28/30 tablets/capsules	6,551,839
296	Rabeprazole 20mg tablet/capsule; 14 tablets/capsules [Items 295 + 296 + 297 will be considered a series]	Class 12 Series 1 (In a Series with Class 10 & Class 11)	Pack of 14 tablets/capsules	8,954,312
297	Rabeprazole 20mg tablet/capsule; 28/30 tablets/capsules [Items 295 + 296 + 297 will be considered a series]	Class 10 Series 1 (In a Series with Class 11 & Class 12)	Pack of 28/30 tablets/capsules	9,307,294
298	Ramipril 2,5mg scored tablet; 28/30 tablets	Class 3	Pack of 28/30 tablets	72,849,993
299	Ramipril 5mg tablet/capsule; 28/30 tablets/capsules	Class 4	Pack of 28/30 tablets/capsules	13,868,603
300	Retinol (Vitamin A) 100 000 iu snip-off, soft gel capsule; 50 blue capsules		Pack of 50 blue capsules	194,621
301	Retinol (Vitamin A) 200 000 iu snip-off, soft gel capsule; 50 red capsules		Pack of 50 red capsules	387,100
302	Retinol (Vitamin A) 50 000 iu snip-off, soft gel capsule; 50 white capsules		Pack of 50 white capsules	40,904
303	Risedronic acid 5mg tablet; 28/30 tablets	Class 5	Pack of 28/30 tablets	62,797
304	Risedronic acid 35mg tablet; 4 tablets	Class 5	Pack of 4 tablets	80,797
305	Risendronic acid 150mg tablet; 1 tablet	Class 5	Pack of 1 tablet	80,797
306	Risperidone 0,5mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,134,242
307	Risperidone 1mg tablet; 28/30 tablets		Pack of 28/30 tablets	2,028,006
308	Risperidone 2mg tablet; 28/30 tablets		Pack of 28/30 tablets	2,974,482



ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
309	Risperidone 3mg tablet; 28/30 tablets		Pack of 28/30 tablets	1,334,086
310	Rivaroxaban 10mg tablet; 30 tablets [Items 310 + 311 +312 will be considered a series]	Class 28 In a series with Class 27 Series 2	Pack of 30 tablets	153,968
311	Rivaroxaban 15mg tablet; 42 tablets [Items 310 + 311 +312 will be considered a series]	Series 2	Pack of 42 tablets	15,756
312	Rivaroxaban 20mg tablet; 28/30 tablets [Items 310 + 311 +312 will be considered a series]	Class 27 in a series with Class 28 Series 2	Pack of 28/30 tablets	157,210
313	Ropinarole 1mg tablet; 84 tablets	Class 24	Pack of 84 tablets	18,955
314	Rosuvastatin 2,5mg tablet; 30 tablets	Class 29	Pack of 30 tablets	34,686,460
315	Rosuvastatin 10mg tablet; 28/30 tablets	Class 31	Pack of 28/30 tablets	2,842,540
316	Rosuvastatin 5mg tablet; 28/30 tablets	Class 30	Pack of 28/30 tablets	17,853,515
317	Senna extract equivalent to Sennosides A and B 13,5mg tablet; 20 tablets		Pack of 20 tablets	3,432,415
318	Sertraline 50mg tablet; 30 tablets	Class 25	Pack of 30 tablets	112,438
319	Sertraline 100mg scored tablets; 30 tablets	Class 26	Pack of 30 tablets	2,846,163
320	Sildenafil 20mg tablet; 90 tablets	Class 23	Pack of 90 tablets	12,504
321	Sildenafil 25mg tablets; 4 tablets	Class 23	Pack of 4 tablets	281,340
322	Sildenafil 50mg scored tablets; 4 tablets	Class 23	Pack of 4 tablets	140,671
323	Silodosin 4mg capsule; 30 capsules	Class 7	Pack of 30 capsules	512,246
324	Silodosin 8mg capsule; 30 capsules	Class 6	Pack of 30 capsules	5,355,668
325	Simvastatin 10mg tablet; 28/30 tablets		Pack of 28/30 tablets	3,530,439
326	Simvastatin 10mg tablet; 28/30 tablets	Class 29	Pack of 28/30 tablets	34,794,460
327	Simvastatin 20mg tablet; 28/30 tablets	Class 30	Pack of 28/30 tablets	17,990,315
328	Simvastatin 40mg tablet; 30 tablets	Class 31	Pack of 30 tablets	2,791,540
329	Spironolactone 100mg tablet; 60 tablets		Pack of 60 tablets	10,905
330	Spironolactone 25mg tablet; 28/30 tablets		Pack of 28/30 tablets	4,683,132

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
331	Spironolactone 25mg tablet; 56/60 tablets		Pack of 56/60 tablets	2,206,940
332	Spironolactone 25mg tablet; 84/90 tablets		Pack of 84/90 tablets	163,635
333	Sulfasalazine 500mg tablet; 100 tablets		Pack of 100 tablets	377,054
334	Tadalafil 20mg tablets; 4 tablets	Class 23	Pack of 4 tablets	187,560
335	Tamsulosin 0,4mg capsule; 28/30 capsules	Class 6	Pack of 28/30 capsules	5,439,648
336	Terazosin 1mg tablet; 28/30 tablets	Class 7	Pack of 28/30 tablets	512,246
337	Terazosin 10mg tablet; 28/30 tablets	Class 8	Pack of 28/30 tablets	1,608,402
338	Terazosin 10mg tablet; 28/30 tablets	Class 6	Pack of 28/30 tablets	5,355,648
339	Theophylline 200mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	1,664,949
340	Thiamine (Vitamin B1) 100mg tablet; 28/30 tablets		Pack of 28/30 tablets	6,221,076
341	Thiamine (Vitamin B1) 100mg tablet; 84/90 tablets		Pack of 84/90 tablets	41,653
342	Topiramate 100mg tablet; 56/60 tablets		Pack of 56/60 tablets	44,552
343	Topiramate 15mg Sprinkle capsule; 60 capsules		Pack of 60 capsules	500
344	Topiramate 25mg tablet; 56 tablets		Pack of 56 tablets	64,478
345	Topiramate 50mg tablet; 56 tablets		Pack of 56 tablets	78,544
346	Tramadol 50mg capsule/tablet; 100 tablets/capsules		Pack of 100 tablets/capsules	3,381,783
347	Tramadol 50mg capsule/tablet; 20 capsules/tablets		Pack of 20 capsules/tablets	10,038,654
348	Tramadol 100mg capsule/tablet; 60 capsules/tablets		Pack of 60 capsules/tablets	305,682
349	Trandolapril 0,5mg capsule; 30 capsules	Class 3	Pack of 30 capsules	72,849,993
350	Trandolapril 2mg capsule; 30 capsules	Class 4	Pack of 30 capsules	13,868,603
351	Tranexamic acid 500mg tablet; 100 tablets		Pack of 100 tablets	9,696
352	Tranexamic acid 500mg tablet; 30 tablets		Pack of 30 tablets	411,284

ITEM LIST

HP09-2026SD

Item No	Items Specification	Therapeutic Class / Series Numbers	UNIT (Use for Estimate & Price)	Estimate
353	Vardenafil 5mg tablets; 4 tablets	Class 23	Pack of 4 tablets	187,560
354	Vardenafil 10mg scored tablets; 4 tablets	Class 23	Pack of 4 tablets	93,780
355	Valproate sodium 100mg crushable tablet; 100 tablets		Pack of 100 tablets	98,060
356	Valproate sodium 133,2mg and Valproic acid 58mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	2,753,153
357	Valproate sodium 199,8mg and Valproic acid 87mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	4,556,064
358	Valproate sodium 333mg and Valproic acid 145mg modified release tablet; 56/60 tablets		Pack of 56/60 tablets	5,005,407
359	Valsartan 160mg tablet; 28/30 tablets	Class 18	Pack of 28/30 tablets	1,023,431
360	Valsartan 40mg tablet; 28/30 tablets	Class 17	Pack of 28/30 tablets	1,738,085
361	Venlafaxine 150mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	146,902
362	Venlafaxine 37,5mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	35,847
363	Venlafaxine 75mg tablet/capsule; 28/30 tablets/capsules		Pack of 28/30 tablets/capsules	143,027
364	Verapamil 240mg tablet; 28/30 tablets		Pack of 28/30 tablets	42,628
365	Verapamil 40mg tablet; 84/90 tablets		Pack of 84/90 tablets	97,304
366	Warfarin 5mg scored tablet; 100 tablets		Pack of 100 tablets	393,772
367	Zinc 20mg tablet; 10 tablets		Pack of 10 tablets	294,488
368	Zinc 20mg tablet; 100 tablets		Pack of 100 tablets	185,705